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ABSTRACT
Extrahepatic biliary strictures are mainly managed using stents when treated 
endoscopically. At present, the main stent types in clinical practice are non-
expandable plastic stents (NEPS) and self-expandable metallic stents (SEMS), with 
an up to tenfold cost for the latter. In current praxis, SEMS are widely used for 
palliative management of malignant biliary strictures as they have longer patency. 
The role of SEMS in preoperative stenting and the management of benign biliary 
strictures (BBS) are unclear.
The main purpose of this study was to describe the therapy outcome of metallic 
stenting in anastomotic strictures of liver transplanted (LT) patients, to compare 
stenting with NEPS and SEMS preoperatively preceding pancreaticoduodenectomy 
and in BBS caused by chronic pancreatitis (CP) and, finally, to describe stenting of 
BBS using covered SEMS (cSEMS), a new technique that has not previously been 
possible, particularly in patients with surgically altered anatomy.
The therapy outcome of 17 LT patients with anastomotic biliary stricture or 
leakage treated with cSEMS was retrospectively analyzed in the piloting study (I). 
In Study II, the stent success and the surgical outcome of 191 patients preoperatively 
stented, with either NEPS or SEMS who had undergone pancreaticoduodenectomy 
or total pancreatectomy were analyzed in a retrospective manner. As a supplementary 
group, 166 preoperatively unstented and 9 percutaneously, transhepatically drained 
patients were evaluated concerning surgical outcome. A prospective, randomized, 
controlled trial was conducted in Study III to compare multiple NEPS with cSEMS 
therapy in biliary strictures caused by CP, with 30 patients in each group. Study IV 
presented three patient cases along with detailed description of equipment, devices, 
technique and outcome, when using cSEMS for BBS in patients with altered anatomy.
The median stenting time for the LT patients (I) was 6.8 months (0.9–10.1). 
The overall stent migration rate was 24%; 100% for Wallstent™ (n=3), 4% for 
Allium™ (n=13) and 0% for a custom-made Micro-Tech (n=2) stent. There were 
two recurrences, but eventual stricture resolution was achieved in all patients after 
restenting. The median follow-up was 21.7 months (6.6–32.0) after stent removal.
For the preoperatively stented patients (II), the stent failure rate was 7.4% (95% 
confidence interval [CI] 4.0%–12.3%) for NEPS and 3.4% (95% CI 0.1%–17.7%) for 
SEMS, (p=0.697). Among the NEPS stented patients, 45% with a pre-stent bilirubin 
level exceeding 50 μmol/l reached a preoperative level of 20 μmol/l or less, compared 
with 26% in the SEMS group (p=0.110). A level lower than 50 μmol/l was achieved 
by 80% of patients in the NEPS group and by 61% in the SEMS group (p=0.058). 
The bile juice bacterial scores did not differ between the differently stented patients, 
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but a statistically significant difference was found when the proportion of sterile bile 
juices in unstented patients with biliary obstruction (100%; n= 7/7) was compared 
with that of the stented patients (1%; n=1/155; p<0.001). Postoperative infection 
complications did not show any significant difference when comparing these stented 
and unstented groups with biliary obstruction. However, the number of unstented 
patients with biliary obstruction was very small. Overall postoperative infections, 
postoperative pancreatic fistulas or reoperations showed no significant difference 
between study groups.
For the patients with CP and BBS (III), the median follow-up was 40 months 
(range 1–66 months). The stricture-free success rate at two years was 90% (95% 
CI 72%–97%) in the NEPS group and 92% (95%CI 70%–98%) in the cSEMS group 
(p=0.405). One late recurrence in the NEPS group, 50 months after stent removal, 
decreased the success rate to 72% (95% CI 27%–92%). The migration rate was 10% 
in the NEPS group and 7% in the cSEMS group (p=1.000).
Three patients with altered anatomy and BBS successfully received an 
endoscopically deployed cSEMS, two of them utilizing the rendezvous technique, 
as the percutaneous transhepatic cholangiogram (PTC) route was available when 
the procedure was started (IV).
In conclusion, endoscopic therapy with cSEMS is safe and efficient both regarding 
anastomotic complications after LT and CP-induced BBS. Progressive stenting with 
NEPS is a good alternative in BBS caused by CP, however, with impaired patient 
comfort. In ordinary preoperative stenting, SEMS do not seem to offer any advantage 
over NEPS. In patients with altered anatomy, endoscopic deployment of cSEMS in 
BBS has become possible, as equipment and devices have evolved.
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1. INTRODUCTION
Traditionally biliary strictures have been treated either surgically or by percutaneous 
transhepatic biliary drainage (PTBD). As the endoscopic devices have evolved, 
endoscopic methods have increasingly been utilized.
In stent therapy, non-expandable plastic stents (NEPS) were the only ones available 
for some time. In the treatment of biliary strictures the limited diameter (up to 11.5 
Fr; 3.8 mm) of NEPS in single-stent therapy is associated with stricture recurrence. 
This can be overcome with balloon dilation and multiple stenting, requiring, 
however, several successive endoscopic retrograde cholangiopancreatography 
(ERCP) procedures. When self-expandable metallic stents (SEMS) with a larger 
diameter (expanding to 8–12 mm) became available, their use was limited to 
malignant strictures since they could not be removed due to tissue imbedding. 
Later, covered metallic stents (cSEMS) enabling stent removal were developed. 
These can be partly covered (pcSEMS) or fully covered self-expandable metallic 
stents (fcSEMS). It is still not known whether stenting with multiple plastic stents 
or cSEMS is preferable in benign biliary strictures.
Biliary reconstruction in liver transplants mainly consists of choledocho-
choledochal (CC) anastomoses in patients receiving the transplant for indications 
other than primary sclerosing cholangitis (PSC), biliary atresy, and Caroli disease 
when reconstruction with a hepaticojejunostomy (HJ) most often is used. The CC 
anastomosis enables traditional therapeutic ERCP, in contrast to a HJ with Roux-
en-Y reconstruction, which was endoscopically inaccessible until only a few years 
ago.
Preoperative biliary drainage (PBD) has been used prior to 
pancreaticoduodenectomy in jaundiced patients, as obstructive jaundice is associated 
with impaired hepatic function, coagulation disturbances, and development of 
cholangitis. Recent studies have, however, shown routine PBD to offer no benefit 
over early surgery (within two weeks) without PBD(1-3). Since early surgery is not 
always possible, PBD still plays a role. Preoperative biliary drainage using SEMS 
has been suggested to drain the biliary tree more efficiently than NEPS and also 
to correlate with a lower postoperative complication rate. As the cost for SEMS 
is significantly higher than that for plastic stents, an evaluation of this kind of 
temporary preoperative use is needed.
After total or partial gastrectomy with Billroth II or Roux-en-Y reconstruction, 
pancreaticoduodenectomy, some duodenal or choledochal injuries, LT with HJ and 
Roux-en-Y gastric bypass (RYGB) for morbid obesity, the anatomy is surgically 
altered, making traditional ERCP with a duodenoscope difficult and often impossible. 
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The percutaneous transhepatic cholangiogram route was the only access to the 
biliary tree until only a few years ago, when device-assisted endoscopy with either 
double-balloon, single-balloon, or spiral enteroscopy enabled endoscopic access. 
Even though the papilla or HJ can be reached, the length of the endoscope and/
or the narrow diameter of the working channel limit the use of traditional ERCP 
accessories. However, the equipment is continuously evolving.
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2. REVIEW OF THE LITERATURE
2.1  ENDOSCOPIC RETROGRADE 
CHOLANGIOPANCREATOGRAPHY
Since McCune first described ERCP in 1968, it has evolved tremendously. There 
are still indications (i.e. PSC) for pure diagnostic ERCP, but the emphasis lies on 
therapeutic procedures. The diagnostic dimension has mainly been replaced by 
various imaging modalities such as magnetic resonance cholangiopancreatography 
(MRCP). Extrahepatic biliary strictures are most often handled using stents when 
managed endoscopically (4).
2.2  STENT TYPES IN BILIARY STENTING
2.2.1  NON-EXPANDABLE PLASTIC STENTS
Most plastic stents consist of polyurethane, Teflon™, or polyethylene (5). The shape 
of biliary NEPS is often slightly curved to obviate migration and to suit the common 
bile duct (CBD) contour. There can be side holes to enable drainage in cases of stent 
tip imbedding in the CBD or the intestinal wall. However, side holes are suspected of 
enhancing stent clogging, which is why stents with antimigratory side flaps lacking 
side holes (Tannenbaum™ stent) have been developed. Polyethylene models appear 
to allow obstruction relief more often than Tannenbaum™ or Amsterdam type 
Teflon™ stents, and the European Society of Gastrointestinal Endoscopy (ESGE) 
guidelines recommend the avoidance of Teflon™ stents when polyethylene stents 
are available. Occluded NEPS should be replaced (6).
The external diameters for biliary NEPS are 7.0, 8.5, 10.0, and 11.5 Fr and 
the standard lengths range between 5 and 18 cm. Some manufacturers offer 
the possibility for longer, custom-made stents when needed. A larger diameter 
is difficult to introduce, however, as the diameter of the working channel on 
standard duodenoscopes is 4.2 mm (5). Nevertheless, larger stenting diameters 
can be achieved by placing multiple stents side by side after balloon dilation. Post-
cholecystectomy bile duct strictures treated with multiple NEPS in a study with a 
small sample (n=20), revealed that hyperplastic tissue on the stricture site, seen 
on cholangioscopy when the stent therapy ended, predicted recurrence, contrary 
to minor strictures with a fibrous ring or no findings at all (7).
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Migration rates of 5.9% for distal and 4.9% for proximal migration have 
been presented for NEPS. Plastic stents migrate more frequently in BBS than in 
malignant biliary strictures (MBS), and single stents more often than multiple stents. 
Distally migrated NEPS are usually spontaneously eliminated, although intestinal 
perforation is a possible, albeit infrequent, complication (8).
2.2.2  SELF-EXPANDABLE METALLIC STENTS
The benefit of SEMS in comparison with NEPS is their expansion to a much larger 
diameter, enabling longer patency. The cost for SEMS is a major disadvantage, as 
it is about ten times that of NEPS. There are numerous types of stents within the 
SEMS group, differing in properties such as design at the ends, shortening ratio, 
radiopacity, covering, radial and axial force, flexibility, mesh cell size, anchoring 
mechanisms, and, consequently, price (5, 9). In vitro measurements have revealed 
markedly different results in radial and axial force between otherwise identical 
covered and uncovered SEMS (9).
The stent design for SEMS intended for extrahepatic bile duct differs from that 
of hilar SEMS. Metallic stents with a central portion with a larger open cell size 
facilitate stenting of the contralateral bile duct with stent-in-stent placement. Hilar 
stents with smaller cell size reducing tumor ingrowth need side-by-side placement. 
There are also Y-shaped hilar stents available (8, 10).
2.2.2.1 Uncovered self-expandable metallic stents
The biliary SEMS are made of metal alloys such as nitinol, stainless steel, Platinol™, 
or Elgiloy™ (5, 9). The metal mesh is either cut from a metal cylinder or braided from 
single or multiple metal wires (5). The open cell size of the metal mesh differs between 
stents, affecting the stent´s features. From a technical point of view, the lower (<5%) 
shortening rate for uSEMS relative to that of cSEMS (20–40%) contributes to an 
easier deployment of the aforementioned (10).
Occluded uncovered self-expandable metallic stents (uSEMS) can be mechanically 
cleansed, although with poor effect for restoring stent patency. Insertion of a second 
cSEMS into the occluded one is recommended to restore stent patency. In cases of 
a life expectancy shorter than 3 months, a NEPS can be chosen instead (6).
16
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2.2.2.2  Partially and fully covered self-expandable metallic stents
To prevent tissue ingrowth, SEMS are covered, thus facilitating stent removal. 
Frequently used materials are polyurethane, silicone, and PTFE (i.e. Teflon™) (5). 
The cover may extend over the entire stent length (fcSEMS) or leave the outer 
ends of the stent uncovered (partially covered SEMS [pcSEMS]).  The pcSEMS 
were originally designed for malignant strictures, but have been used in benign 
indications as well, especially in the early course of SEMS placement in BBS (11). 
Originally, it was thought that the bare ends would prevent migration, but for all 
cSEMS migration is a downside resulting from the covering and lack of ingrowth 
(12-15). The removal of pcSEMS can be impaired due to tissue ingrowth at the 
ends. On the other hand, there are reports of difficult removal of fcSEMS due to 
proximal migration and/or hyperplastic overgrowth at the ends of the stent (16). 
The reported migration rates for fcSEMS are up to 40% (14, 17-20).
Another drawback, connected to cSEMS is de novo strictures arising from a 
different area of the stent than the original stricture. An excessive radial force is 
assumed to induce local ischemia and subsequent stricture. If the stent diameter 
is oversized for the duct, the patient is prone to de novo strictures (15, 21).
When cSEMS were first introduced, a concern was occlusion of the cystic duct 
in patients with intact gallbladder, causing cholecystitis. An increased risk for 
pancreatitis caused by occlusion of the pancreatic duct in the papilla, was noted 
with use of cSEMS (22). Some studies indicate that high axial force of the stent, 
rather than the cSEMS itself, is associated with higher incidences of pancreatitis 
and cholecystitis (23).
Figure 1. Tannenbaum™ plastic stent, uncovered SEMS and fully covered SEMS with 
antimigratory flaps
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2.2.3  BIODEGRADABLE STENTS
Kemppainen et al. described the first animal biodegradable stent (BDS) in 1993 (24). 
Although BDS have been used in humans as well, their use in the pancreaticobiliary 
tract and the gastrointestinal tract in general, is somewhat explorative (25, 26).
The goal and rationale for development of biliary BDS is the potential to achieve 
patency and a radial force similar to that of fcSEMS without the need for stent 
retrieval. Moreover, the NEPS- and cSEMS-related issues regarding stent migration 
and difficult removal could be disregarded (26).
The most commonly used BDS materials are polyglycolide (PGA), poly-capro-
lactone (PCL), polylactic acid (PLA), polydioxanone (PDX) and poly-lactide-co-
glycolide with a magnesium alloy base (25). The degradation of the polymers is well 
known because of their previous use as suture materials. The slower (3–6 months) 
degradation and higher flexibility of PDX seems to be beneficial, as this may help in 
preserving the mechanical properties of the stent longer than with other polymers 
(27).  The majority of pancreaticobiliary BDS reports are animal studies (28-32).  In 
humans, the biliary BDS have been inserted using the PTC route, as no endoscopic 
insertion device was available (27, 33). In 2010, Hajer et al. reported the placement 
of an Ella™Dv stent using a mother endoscope to facilitate the insertion of the 
15 Fr introduction sheath (31). Recently, Siiki et al. reported the first endoscopic 
insertion of a custom-made biliary PDX BDS in postoperative cystic duct leakage 
using a standard duodenoscope (34).
One challenge related to BDS is the lack of radiopacity in the materials (30). 
This can be overcome by mixing barium sulphate into the biodegradable stent 
material or by adding radiographic markers to the stent (25, 28, 30, 35). Another 
challenge is that the currently available Ella™Dv stent requires a 15 Fr sheath to 
be introduced (27). Therefore, the placement has been percutaneous, except for 
the previously mentioned report using a mother endoscope for the procedure (27, 
31). Concerns regarding the impact of the stent material and degradation on the 
duct tissue have been raised. A porcine study on biliary stenting using a PDX stent 
showed transient, mild, or moderate hyperplasia of the ductal mucosa (31).
2.2.4  DRUG-ELUTING, DRUG-COATED, AND RADIOACTIVE STENTS
To overcome the problem of stent clogging or impaired stent patency, particularly 
in MBS, preliminary research has been conducted on drug-processed stents. 
Gemsitabin, sorafenib and paclitaxel have been investigated (8, 36, 37). Paclitaxel has 
a mitosis inhibiting effect, antiproliferative activity and antifibrotic effects, justifying 
its piloting use in BBS (38).  Animal models have mainly been used, but human 
pilot studies have also been conducted. A prospective, human, piloting, randomized 
controlled trial (RCT) compared paclitaxel-eluting cSEMS with conventional cSEMS 
18
2. REVIEW OF THE LITERATURE
regarding patency and survival and showed no statistically significant difference 
between the stents (39). A paclitaxel study on mice revealed growth inhibition of 
pancreatic cancer and cholangiocarcinoma (CCA) by suppressing angiogenesis (40). 
The in vivo study by Farnbacher et al. showed significantly reduced encrustation in 
heparin-coated NEPS compared with uncoated NEPS, albeit without any clinical 
impact (41). As sludge clogging the stents contains bacteria, microbial byproducts 
and crystals of fatty acid, the impact of antibiotics and/or ursodeoxycholic acid on 
stent patency has been evaluated, but has shown no significant effect (42).
With the purpose of impairing tumor growth and prolonging patency, a 
radioactive agent, iodine-125 seed, can be implanted in a stent, forming kind a of 
brachytherapy (43). Brachytherapy using holmium-166 has been shown to be safe 
in a canine model (8).
2.2.5  STENT FEATURES WITH FUNCTIONAL CONSEQUENCES
To overcome or compensate certain stent-related drawbacks and complications, 
several stent features have been developed. The above-mentioned drug-coating and 
drug-eluting can be considered as functional properties of a stent. Antimigratory 
stent elements used on (c)SEMS are anchoring pins protruding from part of the 
stent, flared ends, and anchoring flaps (43). These elements have been used alone 
and in combination, and furthermore, they can be located in different parts of the 
stent. There are also NEPS with anchoring flaps (5). Recently, Walter et al. reported 
a fairly high migration rate, 31%, when a nitinol fcSEMS with bilateral flare ends and 
irregular cellspaces was used (20). On the other hand, a study of otherwize similar 
fcSEMS, with or without flared ends, revealed a 40% migration rate with stent ends 
flared, compared with a migration rate of 100% when unflared stents were used (8). 
Mangiavillano et al. reported a migration rate as low as 3.3% using a new fcSEMS 
with proximal anchoring flaps and a double lasso system for retrieval, enabling 
intracholedochal deployment with no need for the stent to cross the papilla (44).
Weigt et al. very recently reported the use of a double-coned cSEMS mimicking 
the spindle-shape of the CBD, with the purpose of reducing the migration rate in 
11 patients. The distal part of the stent was 12 mm, with a diameter diminishing 
towards the duodenal end. The stent was at its narrowest (6 mm in diameter) 15 
mm from the duodenal end, whereafter the diameter increased again in a cone-like 
shape. The mechanical properties of the stent were measured and compared with 
those of a cylindrical shape from the same manufacturer, revealing that the radial 
forces at different points of the double-coned stent were less than half of those of 
the cylindrical stent. No migrations occurred, but three cases of stent occlusions 
were observed, two of them followed by cholangitis. Two recurrences (one CP and 
one AS stricture) were seen (45).
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In 2009 Misra et al. reported that all patients in their study on biliary SEMS across 
the papilla had duodenobiliary reflux, constituting a risk for ascending cholangitis 
(46). This raised a theory on bile-food mix and biofilm induced stent clogging, and 
stents with antireflux valves were developed (43). Often the drawback cited for these 
stents was impaired drainage. However, some studies showed increased patency 
when antireflux stents were used (8).
Benign anastomotic strictures are usually short. The use of long cSEMS exposes 
the sound duct tissue to pressure injuries like necrosis and fibrosis (47). Short 
cSEMS, again, are prone to migrate outside the stricture site (43). To prevent 
migration, the short stents can be shaped to, for example, have a waist thinner 
than the ends (48). To ease removal, a snare or a lasso hanging in the duodenum, 
can be attached (11, 43, 48).
When it comes to the NEPS, the new stent designs seem to focus on more pliable 
materials with the intention of reducing migration rates, as the stent more easily 
could conform to the shape of the CBD (8).
2.3  IMPACT OF STENT POSITION IN RELATION TO THE 
PAPILLA
In 1998, Pedersen et al. published an RCT on MBS patients with the idea that the 
placement of the stent (NEPS) above an intact sphincter of Oddi might prevent 
migration of bacteria and deposition of organic material into the stent (49). There 
was no significant difference in overall stent performance between supra- and 
transpapillary positioned stents, even though stents placed above the sphincter of 
Oddi migrated more frequently.  On the other hand, two small sample size studies 
with 13 and 10 patients, respectively, reported no migrations when, custom-made 
fcSEMS of length 4 cm were placed intraductally (11, 48). Another study revealed 
significantly longer patency for suprapapillary NEPS, but the number of patients 
in this study was fairly low (50).
2.4 BENIGN BILIARY STRICTURES
2.4.1  ETIOLOGY AND CLASSIFICATION
The most common type of BBS in Western countries is the postoperative stricture, 
which can occur secondary to intraoperative injury, most often after cholecystectomy. 
Anastomotic strictures also occur after orthotopic LT or following bile duct 
reconstructions (51). In CP, strictures develop in the intrapancreatic portion of the 
CBD. Infections including tuberculosis, histoplasmosis and the liver fluke Clonorchis 
sincesencis (common in Asia) can cause BBS as well as HIV cholangiopathy. Other 
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causes include PSC, sarcoidosis, recurrent cholangitis, abdominal trauma, ischemic 
injury, radiation- and chemotherapy, Mirizzi syndrome, vasculitis, papillary stenosis, 
choledochal cyst and dysfunction of the sphincter of Oddi. The etiologies can be 
classified as intrinsic or extrinsic, CP constituting the most common cause of the 
latter (52).
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In 1982 Bismuth classified postoperative biliary strictures based on their location, 
and other classifications for postoperative bile duct injuries have since been 
presented (53).
Figure 2. The Bismuth classification of benign biliary strictures based on stricture location. The location 
affects the repair technique.
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2.4.2 CLINICAL PRESENTATION AND DIAGNOSIS
Clinical presentation varies from slightly elevated blood liver function tests to 
complete cholestatic syndrome, including jaundice, pruritus, dark urine and whitish 
feces(54). Cholangitis can complicate the biliary obstruction, and CBD stones may 
occur above the stricture. Secondary biliary cirrhosis may develop as a long-term 
consequence in chronic cases (55).
The diagnosis is made based on elevated liver function tests and/or bilirubin 
levels and US scan of the upper abdomen, revealing dilated bile ducts. History of 
previous surgery on the biliary tree and its surroundings is crucial to evaluate the 
possibility of postoperative strictures (54, 56). Tumor markers can be helpful when 
a differential diagnosis for malignant cases is needed (57).
2.4.2.1 Transabdominal ultrasound
Ultrasound detects biliary obstruction along with the level of obstruction, with an 
accuracy exceeding 90%. The accuracy of detecting the underlying cause is much 
lower and varies from 30% to 70% (56). 
2.4.2.2  Magnetic resonance imaging
Often MRCP is performed to evaluate the biliary tree and MRCP is the current 
non-invasive diagnostic method of choice for biliary strictures (58) . The sensitivity 
for the underlying cause of biliary obstruction is as high as 98%. The sensitivity in 
differentiating benign strictures from malignant strictures varies from 30% to 98% 
(56). Hepatocyte-specific MRI contrast material can help in distinguishing partial 
strictures from complete ones when using delayed phase imaging, as the contrast 
material is excreted into the biliary tree from the hepatocytes (58) .
2.4.2.3  Multiphase contrast-enhanced computed tomography
Computed tomography (CT) facilitates detection of the underlying cause of biliary 
obstruction, and reveals complications such as cholangitis and cholangitic abscess. 
CT helps to differentiate between benign and malignant strictures, although the 
distinguishing between CP-induced obstruction and MBS can be challenging. 
Malignant strictures are characterized by hyperenhancement and wall thickening. 
CT also reveals pathologic lymph nodes and metastases. Positron emission 
tomography (PET)-CT is helpful in unclear cases, offering a sensitivity and accuracy 
of 92%  (56, 57) .
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2.4.2.4  Endoscopic ultrasound
Sometimes endoscopic ultrasound (EUS) can add information to the diagnosis 
(59) . It provides the possibility of accurate, guided fine needle aspiration. EUS is, 
however, highly user-dependent (56) .
2.4.2.5  Endoscopic cholangioscopy
The currently widely used single-operator cholangioscopy is the SpyGlass™ Direct 
Visualization system (Boston Scientific Corp, MA, USA). During the procedure 
the SpyScope™ delivery catheter is introduced through the working channel 
of a therapeutic duodenoscope. The catheter has channels for the optic probe, 
irrigation, and instruments. The scope can be introduced into the bile duct for 
accurate visualization and allows the possibility for biopsies, making this a powerful 
diagnostic tool for biliary strictures (60) .
2.4.3  TREATMENT OPTIONS AND MANAGEMENT OF BENIGN BILIARY 
STRICTURES
Historically, surgery and later PTC procedures have been the management of 
choice in BBS and anastomotic biliary complications (12, 61-63) . Complications 
and difficulties related to the poor condition of patients limit their use, and 
consequently, over the past 20 years, these procedures have been replaced by 
less invasive therapeutic ERCP(13). Complications occuring after ERCP include 
bleeding, perforation, and post-ERCP pancreatitis (PEP) and cholangitis, and there 
are consensus criteria for defining the severity of these complications (64) . Mild 
PEP is clinical pancreatitis with an amylase level higher than three times the upper 
limit at more than 24 hours from the procedure and a 2- to 3-day hospitalization. 
Moderate PEP requires a 4- to 10 day hospitalization. Severe PEP is defined by a 
need for hospitalization of more than 10 days or hemorrhagic PEP, presence of 
a pseudocyst or a flegmon, or need for percutaneous or surgical interventions. 
Initially, the therapeutic ERCP consisted of balloon dilation alone, with limited 
effect, with reported success rates being 27–41% (65). Later, placement of a single 
plastic stent, either with preceding dilation or not, comprised the procedure (66, 
67). In 2001, Costamagna et al. reported successful use of multiple plastic stents in 
benign, postoperative CBD strictures, increasing the stent number in consecutive 
procedures (68) . Endoscopic treatment with NEPS is burdened by the need for 
repeat ERCPs and stent exchange due to clogging every 3–4 months over a time 
period of 1–2 years (13, 69, 70). Definitive stenting with uSEMS, and later, when 
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available, with removable cSEMS were taken into use at the beginning of the 21st 
century (55, 71, 72)
Actually, it is not unequivocal whether stents should be placed instead of sole 
balloon dilation in all circumstances (38). If endoscopic access for some reason is 
hindered, PTBD can be performed (73). In some cases the PTC route can be used 
for rendezvous procedures (74).
Recently, Hu et al. performed intraductal radiofrequency ablation previously 
used in malignant cases for nine refractory BBS with a 56% success rate. The 
strictures were both intra- and extrahepatic and had various etiologies (75). 
2.4.4  ANASTOMOTIC BILIARY COMPLICATIONS AFTER LIVER 
TRANSPLANTATION
Post-LT biliary complications occur in 5–35% of cases(63). For deceased donor 
LTs the incidence is 5–15%, whereas for living donor LTs the figures range from 
28% to 32% (76). Post-LT bile duct strictures can be classified as non-anastomotic 
(NAS) or anastomotic (AS), the latter accounting for about 40% of all post-LT biliary 
complications and up to 87% of post-LT BBS (62, 65, 76). The reported incidence 
for post-LT AS is 4–13%(65).
The incidence for post-LT anastomotic biliary leakage is 7% (77).
The most common bile duct reconstruction in LT is CC anastomosis (78, 79). 
Choledocho- or hepaticojejunostomy reconstruction is often used in LT indicated 
by PSC, biliary atresy and Caroli disease affecting the intrahepatic biliary tree (79).
2.4.4.1  Pathogenesis of and risk factors for post-LT anastomotic complications
The AS is thought to result from suboptimal surgical technique causing ischemia and 
as a result of fibrotic healing (76, 80). Risk factors are previous or simultaneous bile 
leakage, small bile duct caliber, size mismatch between donor and recipient including 
female donor/male recipient pairs, inappropriate suture material, anastomotic 
tension, infection and pedantic hemosthasis by electrocautery (62, 80). Albert et 
al. revealed a significant increase in AS in patients with viral or toxicity-induced 
hepatocellular carcinoma (HCC) in the recipient´s cirrhotic liver (81).
2.4.4.2  Management of post-LT anastomotic biliary complications
Treatment with NEPS. The technique with multiple plastic stenting was brought into 
use in post-LT AS as well, with success rates of up to 94% (63, 67, 68). There are also 
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dissenting opinions regarding such an aggressive approach in early postoperative 
anastomotic complications, reasoning that the acute, potentially reversible, local 
ischemia superimposed by edema will resolve if biliary ductal drainage is maintained 
by a single stent (67, 82). Progressive pneumatic dilation with double plastic stent 
placement has been considered the standard treatment for post-LT strictures (70).
A retrospective report of 47 patients´ stricture recurrence after multiple plastic 
stenting identified late (> 6 weeks) occurrence of the stricture to be a significant 
risk factor for relapse, as was a high-grade (a luminal narrowing of at least 90%) 
stricture. There was also a tendency of recurrence in patients with hepatitis C virus 
(HCV), but competing risk analysis abated this finding (81).
Treatment using cSEMS. In 2006, Vandenbroucke reported the use of pcSEMS in 
post-LTstrictures leaving the stent in place in the CBD (72). In cases of lost stent 
patency, surgery with a HJ was performed. In 2009 and 2010, two small sample 
size (n= 11 and 16) reports on deployment of fcSEMS in post-LT AS and/or leakages 
after failed endoscopic NEPS therapy were published with promising results (19, 
83). Migration, without clinical consequences, was seen in 38% and 56% of patients. 
Recurrence or other treatment failure was seen in 6% and 30 % of cases. Tarantino 
et al., on the other hand, reported 71.8% success and 14.3% recurrence rates in 
post-LT AS and/or leakage when deploying fcSEMS for patients following failure 
of treatment with NEPS. In patients with fcSEMS as the first-line approach, the 
figures were 53.3% and 25.0%, respectively, and the authors concluded that fcSEMS 
placement is neither useful nor recommended as the first-line approach in post-LT 
AS. The migration rates for the first-line and second-line approach groups of 46.7% 
and 33.3%, respectively, were thought to explain the fairly high recurrence rates (70).
Phillips et al., again, in 2011, published a report on 17 patients with post-LT 
biliary leaks managed by intraductally placed, fully covered Viable™ stents with 
anchoring pins. All patients but one obtained long-term leak control, but six 
(35%) clinically significant strictures were recognized at stent removal, along with 
two (12%) clinically insignificant strictures and two biliary ulcerations confirmed 
on cholangioscopy. Some patients had strictures already when the fcSEMS was 
deployed, but the strictures were at a different site when the stent was removed, 
thus constituting de novo strictures. Furthermore, in two patients with hepatic 
artery thrombosis, the fcSEMS served as a bridge to surgery, controlling the leak 
to manage the infection sufficiently. The authors concluded that fcSEMS cannot be 
recommended for management of post-LT biliary leaks, although they recognized 
the possible influence of donor and hepatic artery factors, and more importantly, 
the choice of a stent with high radial force and anchoring pins, on the development 
of strictures and ulcers (47).
To date, Kaffes et al. have published the only prospective RCT comparing multiple 
plastic stenting with fcSEMS in post-LT AS.  Stricture resolution was achieved in 
25
80% and 100% of cases, respectively, with a nonsignificant difference. The number 
of ERCPs needed was significantly lower (2 vs 4.5, p = 0.0001) in the fcSEMS 
group, and fcSEMS placement was also more cost-effective. Furthermore, there 
was a non-significant tendency towards fewer complications in the fcSEMS group 
(p = 0.051).  The median treatment time was 10.1 and 3.8 months, respectively and 
the corresponding recurrence rates were 37.5% and 33.3%. The number of patients 
in each group was 10 (48).
Other treatment options. Previously, coronary and crural arterial stenoses have 
been treated with intravascular paclitaxel-eluting, dilating balloons. A German 
group tried this procedure on 13 post-LT AS and showed a 92% (12/13) success 
rate. Two of the patients needed three interventions, one two interventions and the 
remaining nine one procedure only. The authors suggested further randomized, 
large-scale trials (38).
2.4.5 BILIARY STRICTURES IN CHRONIC PANCREATITIS
Chronic pancreatitis induced CBD strictures are seen in 3–23% of cases (84). If the 
stricture is caused by inflammation or pseudocyst compression, it can be reversible, 
whereas a fibrotic stricture is irreversible (85). The ESGE guidelines recommend 
intervention for CBD strictures caused by CP in cases of symptoms, secondary 
biliary cirrhosis, presence of bile duct stones, progression of the stricture, or when 
unicteric cholestasis (i.e. serum alkaline phosphatase [AFOS] level greater than 
twice the upper limit) persists for longer than one month (86).
Even though surgery, consisting of Frey´s procedure (coring out the diseased 
portion of the pancreas in combination with lateral pancreaticojejunostomy allowing 
biliary and pancreatic drainage), is considered the golden standard for treatment 
of CP-induced BBS, endoscopic treatment with multiple plastic stents is currently 
the first-line treatment choice as it is less prone to complications and also suits 
surgically unfit patients (59, 86, 87).
2.4.5.1 Management of biliary strictures in chronic pancreatitis
Treatment with NEPS. In the treatment of distal CBD stricture secondary to CP, the 
long-term clinical success rate has been reported to be 24% following single stent 
therapy versus 92% for multiple stent therapy (88). Other studies have revealed 
success rates ranging from 8% to 38% following single stent therapy and figures 
of 60–92% after multiple stent therapy (6, 88-90). Multiple stent therapy requires 
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several consecutive ERCP procedures, approximately trimonthly, in order to change 
clogged stents and increase the number of stents after balloon dilation (13, 68, 70).
Treatment using cSEMS. To overcome the inconvenience stemming from the need 
for stent exchange and amendment when plastic stents are used, cSEMS were 
brought into use also in CP-induced BBS (91, 92). Another argument for treatment 
with cSEMS is the lack of patient compliance with multiple procedures in this 
patient group, which often uses alcohol abundantly (57). The cSEMS durations 
in treatment of BBS in CP varies from 2 months to 1 year, with long-term success 
rates ranging from 46% to 93% (13, 52, 87, 91-93).
The main drawback with fcSEMS is their propensity to spontaneous migration 
(57, 92, 94).
Although, reports exist on definitive treatment with uSEMS (i.e. there is 
no intention to remove the stent) in CP patients, at present uSEMS are almost 
abandoned in benign states, as there are removable covered stents available (57, 71).
2.5  MALIGNANT BILARY STRICTURES
Malignant biliary strictures may result from direct tumor infitration, extrinsic 
compression, adjacent inflammation, desmoplastic reaction (i.e. growth of 
connective tissue) or combinations of these (95). The tumor etiologies include 
pancreatic cancer, ampullary cancer, CCA, gallbladder cancer and metastatic disease 
expressed as an intrahepatic mass or lymphadenopathy (96-98). Fewer than 20% 
of these patients are candidates for curative resection, either being poor surgical 
candidates or having unresectable disease due to local spread or distant metastases 
(98). Biliary obstruction develops in 70–90% of unresectable cases, with endoscopic 
procedures as the treatment of choice for palliation (6, 95, 98). Preoperative biliary 
drainage for malignancy is debatable (1-3, 99-103).
Table 2. Etiology of malignant biliary strictures.
PANCREATIC CANCER CHOLANGIOCARCINOMA
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2.5.1  PALLIATIVE STENTING OR DRAINAGE
Endoscopic palliative drainage is effective in >80% of cases with a morbidity 
lower than in surgical interventions (6, 96). Large-bore SEMS have clearly longer 
patency than plastic stents (10). According to the ESGE guidelines, initial insertion 
of a NEPS is cost-effective in cases with a life expectancy shorter than 4 months; 
otherwise stenting with SEMS is more cost-effective (6). Another study drew the 
line at 6 months (104). The median patency for SEMS in MBS has been 9 months 
(98). A recent, randomized trial comparing the functional stent times for NEPS, 
uSEMS and pcSEMS showed a significantly longer functional time for SEMS (9–10 
months vs. 5 months), without any significant difference in total cost per patient 
at one year (105). No difference in cost was present between uSEMS and pcSEMS. 
Furthermore, the total cost for patients with a short (less than 3 months) survival 
time not differ between NEPS and SEMS. Another prospective RCT from 2013 
compared efficacy and complications for pcSEMS and NEPS in palliative stenting, 
revealing a significantly longer time to stent failure for pcSEMS (12 months) than 
for NEPS (5 months), and a fivefold cholangitis rate in the NEPS group (106). 
If cSEMS are used, their tendency to migrate might outweigh the advantage of 
long stent patency and also spoil the argument for cost-effectiveness (23). Routine 
placement of NEPS in palliative conditions is not recommended, as their patency 
is limited to about 3 months (96, 98). If NEPS are used, approximately 50% of the 
patients require stent exchange due to clogging(96). A recent report by Nakai et al. 
recognized cSEMS with a low radial force, chemotherapy, and duodenal invasion 
as significant risk factors for cSEMS migration in distal MBS (23).
Besides longer patency due to their larger diameter, SEMS have the advantage 
of a relatively narrow, 8 Fr delivery system, making the passage across the stricture 
easier (96).
The downside of uSEMS, which were used from the beginning of the metal 
stent era, is eventual dysfunction due to tumor ingrowth and/or overgrowth (10, 
98). To overcome this problem, cSEMS were developed (10, 23). Kitano et al. 
prospectively, in a RCT, compared partially covered and uncovered SEMS (n= 
60+60) in the palliation of distal biliary obstruction due to unresectable pancreatic 
cancer. Both stents had a relatively low axial force and uncovered, flared ends to 
prevent migration. Both patient survival without stent dysfunction (median: 187 
vs. 132 days; p = 0.043) and stent patency (mean ± SD: 219.3 ± 159.1 vs. 166.9 ± 
124.9 days; p = 0.047) were significantly longer in the pcSEMS than in the uSEMS 
group. Reintervention for stent dysfunction was performed on 23% of  pcSEMS 
patients and 37% of uSEMS patients, with a non-significant difference (p = 0.08). 
No migrations occurred in either group (107).
The use of cSEMS in MBS raised concerns regarding cholecystitis and pancreatitis, 
as it did in BBS. A meta-analysis from 2013 did not reveal any differences in 
pancreatitis or cholecystitis rates between uSEMS and cSEMS (108) . The ESGE 
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guidelines recognized neoplastic involvement of the cystic duct and gallbladder 
stones as key risk factors for SEMS-related cholecystitis (5).
Meta-analyses comparing uSEMS with cSEMS regarding stent patency in 
patients with MBS, have revealed a longer patency for cSEMS, with others finding 
an unclear benefit of cSEMS, as their migration rate is higher and they do not appear 
to have longer patency (108-110). A recent Swedish RCT revealed no difference 
in stent patency (median 153 vs. 127 days) or survival (median 154 vs. 157 days) 
between patients stented with covered or uncovered SEMS, suggesting that other 
factors, including cost, availability, stent length and personal preference, play a 
more important role in stent choice (111).
Cholangiocarcinoma can be classified based on location as intrahepatic, 
perihilar, and extrahepatic (112). Bismuth proposed a CCA classification with further 
subclassification of hilar tumors with respect to their proximal extension (98). In 
cases of unresectable disease with jaundice, biliary drainage is the treatment of 
choice (112). In cases of extrahepatic lesions, the principles of extrahepatic malignant 
stenting are applicable (98, 112). Hilar stenting, on the other hand, requires 
consideration of whether to perform uni- or bilateral stenting, and whether to use 
NEPS or SEMS, among other considerations (8, 10, 112).
As drainage by ERCP has been shown to be both safer and more successful, 
PTBD has been recognized as a salvage method in cases of unsuccessful endoscopic 
therapy or in cases of substantial intrahepatic disease (96, 112, 113).
If the diagnosis is uncertain at the time of biliary drainage, according to the 
ESGE guidelines, a plastic stent is preferred to avoid long-term complications of 
SEMS in benign strictures (6).
2.5.1.1  Malignant biliary strictures in altered anatomy
All reports on percutaneously administered SEMS in altered anatomy comprise 
malignant strictures for which uncovered self-expandable metallic stents (uSEMS) 
were used (114, 115). In 2009, Koornstra et al. presented a case report where a 
uSEMS was inserted with the rendezvous-DBE technique into a malignant stricture 
of the HJ (115). Primarily, the PTC route could be used only for drainage since the 
correct route to reach the jejunum could not be found. A more recent case report 
by Pinho et al. describes SEMS placement in a malignant stricture through the 
papilla with the rendezvous technique using SBE (116).
29
2.5.2  DISEASE-MODIFYING TREATMENT
In unresectable CCA, ERC has been combined with photodynamic therapy (PDT) 
utilizing the cytotoxic effect of light and a photosensitizing chemical produced locally 
at the stricture site (96, 112). At the end of the procedure a stent is usually inserted. A 
longer SEMS patency has been demonstrated when the stent is inserted immediately 
after local PDT therapy (112). In 2005 Zoeph et al. published a RCT showing that 
PDT and stenting significantly improved survival (21 vs. 7 months) compared with 
stent therapy alone in patients with unresectable CCA(117). This survival benefit 
has later been demonstrated in several heterogeneous cohort studies (112).
Intraductal, ERCP-directed radiofrequency ablation (RFA) was developed as a 
tool for endoscopy to induce necrosis in MBS (112) . Contrary to local PDT, intraductal 
RFA does not seem to prolong stent patency, but appears to be an independent 
predictor of survival (118) . Local RFA has also been used for management of tumor 
ingrowth in biliary uSEMS (112) .
Adverse issues when using PDT include photosensitivity, with the need to avoid 
sunlight for 4–6 weeks, and, depending on the photosensitizer used, the cost, which 
can be thirtyfold that of a RFA catheter (112). The advantage regarding PDT is that 
laser light can travel through bile, whereas RFA needs direct tissue contact (112). 
2.5.3  PREOPERATIVE BILIARY DRAINAGE
Obstructive jaundice correlates with impairment of hepatic function, development 
of cholangitis and disturbances in coagulation (119). Surgery during obstructive 
jaundice was recognized to correlate with higher risks already by Whipple in 
1935, with similar reports up to 50 years later (120, 121). Whipple actually 
conducted a two-stage operation with biliary bypass in the first phase, and 
the actual pancreaticoduodenectomy later, when the obstructive jaundice had 
resolved. Preoperative biliary drainage can also be achieved percutaneously and 
endoscopically, the latter comprising the most frequently used method at present 
(122). In recent years, there have been studies reporting no benefit of PBD over 
early surgery within two weeks, whereas other studies have shown some benefit for 
conducting PBD (1-3, 99-101, 123). The use of routine PBD is thus controversial. In 
2010, van der Gaag et al. published a multicenter, randomized trial comparing PBD 
with surgery within a week alone for patients with cancer of the pancreatic head. 
The PBD patients received a NEPS 4–6 weeks prior to surgery, with PTC drainage 
as a rescue alternative in the 6% of patients with unsuccessful endoscopic stent 
placement. The rate for serious complications was 39% in the early surgery group 
and 74% in the PBD group (p<0.001; RR for the early surgery group 0.54). Both 
PBD and surgery-related complications were included in these figures. The overall 
complication rate for PBD was as high as 46%. The difference in surgery-related 
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complications was non-significant (37% in the early surgery and 47% in the PBD 
group, p=0.14; RR for the early surgery group 0.79) (1).
Later, between 2011 and 2014, a new patient cohort, consisting of patients 
with PBD using fcSEMS, was added to these same early surgery and PBD-using 
NEPS cohorts, the two latter functioning as historical controls. The PBD-related 
complication rate for fcSEMS was 24%, giving a RR of 1.9 (p=0.011). The stent-
related complications (i.e occlusion and stent exchange) were 6%, compared with 
31% for the NEPS group (p=0.003). The rate for surgical complications did not 
differ between the groups. The PEP rate for the fcSEMS cohort was higher (18%, 
n=9/49; one severe PEP) than in the NEPS group (p=0.038) (124).
A Cochrane meta-analysis from 2012 revealed a significantly higher occurrence 
of serious morbidity in the PBD group than in the early surgery group (RR 1.66; 
95% CI 1.28 to 2.16; p=0.0002), but no significant difference in overall mortality. 
The conclusion of the meta-analysis was that current evidence could neither support 
nor disprove PBD for patients with obstructive jaundice (125).
While some studies have shown an increase in postoperative infection 
complications and higher overall complication rates after PBD, others have revealed 
no difference or evidence of the above (2, 3, 99, 126-129).
PBD is clearly indicated in the presence of cholangitis or significant hepatic 
dysfunction secondary to prolonged obstruction (100, 122). In biliary obstruction 
PBD is also considered if logistics delay surgery or in cases of neoadjuvant 
chemoradiotherapy (122).
Smith et al. revealed a more favorable early, but not overall, survival in pancreatic 
cancer patients without jaundice. Low albumin (p = 0.016), elevated AFOS (p = 
0.011) and elevated CRP levels (P = 0.021) were associated with poorer overall 
survival, and a bilirubin level > 35 μmol/l at the time of surgery was a significant 
adverse predictor of early survival. However, the majority of these patients had 
undergone PBD (n=130): only 25 had not, and furthermore, only 11 of these were 
jaundiced (101).
Initially, SEMS was thought to be contraindicated in resectable pancreatic cancer, 
as it was assumed that the stent would impair the biliary anastomosis or provoke 
inflammatory and fibrotic reaction around the stenting area, hampering surgical 
dissection (122, 130, 131). Later observations disproved this assumption (130, 132, 
133).
Decker et al. found that PBD patients stented with SEMS had a significantly lower 
stent dysfunction rate than NEPS-stented patients (0/11; 0% vs. 7/18; 39%; p=0.02) 
(134) . Previous, figures of 15% and 93%, respectively, have been published (132).
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2.6  DEVICE-ASSISTED ENTEROSCOPY ERCP
Surgically altered anatomy occurs after total or partial gastrectomy with either 
Billroth II or Roux-en-Y reconstruction, after pancreaticoduodenectomy, duodenal 
or choledochal injuries, LT with HJ and RYGB for morbid obesity. This alteration 
means traditional ERCP with a duodenoscope is difficult and most often impossible 
(135, 136).
The insufficient length of the duodenoscope is the obstacle for performing 
traditional ERCP in altered anatomy.  In recent years, this obstacle has been 
overcome using device-assisted enteroscopy (DAE) using double-balloon (DBE), 
single-balloon (SBE), or spiral enteroscopy (SE) (136, 137). Even though these 
techniques enable the HJ or papilla to be reached, there are still several limitations 
compared with conventional ERCP; the enteroscopes are front viewing unlike 
the lateral viewing duodenoscopes, the enteroscope lacks an elevator forming 
a drawback in cases of difficult cannulation of the papilla and standard ERCP 
accessories can often not be used due the longer and narrow (2.8 mm) working 
channel.  In recent years, short DBE and SBE have become available, enabling the 
use of those conventional ERCP accessories that can be used in a narrow working 
channel (138-141)
2.6.1  MANAGEMENT OF PATIENTS WITH ALTERED ANATOMY USING PTC
Traditionally, in patients with altered anatomy, biliary problems have been 
managed using PTC (142, 143).  However, there is often a need for repeated or 
new interventional procedures. In BBS, the reported success rate using the PTC 
technique is 67–90% (143, 144). Complication rates of 5–35% have been reported 
(144, 145). If bile duct dilation is minor or absent, PTC has a higher complication rate 
or may not be feasible at all (73). Okuno et al. presented a series of six patients with 
altered anatomy and bile duct stone removal using the rendezvous technique after 
forming a puncture route through the gallbladder. They reported no complications 
other than one case of mild post ERCP pancreatitis (PEP) (74).
2.6.2  SURGICALLY ASSISTED TECHNIQUES 
Baron et al. reported an option of using the DBE to insert a percutaneous 
endoscopic gastrostomy tube (PEG) into the resected stomach. Through this 
opening, a duodenoscope could be passed to perform ERCP in altered anatomy 
(4). Law et al. described a series of five RYGB patients who had percutaneous 
assisted transprosthetic endoscopic therapy, where the excluded stomach first was 
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accessed with balloon enteroscopy, a retrograde percutaneous gastrostomy was 
then performed and bridged with an esophageal SEMS to gain antegrade access 
with a standard duodenoscope (146). Schreiner et al. compared DAE ERCP with 
laparoscopy-assisted ERCP through the remnant stomach in RYGB patients. They 
concluded that laparoscopy-assisted method was superior in patients with a Roux-
en-Y and bilioenteric limb exceeding a length of 150 cm (147).
2.6.3  MANAGEMENT OF PATIENTS WITH ALTERED ANATOMY USING SHORT 
ENTEROSCOPES
Short balloon enteroscopes have been developed to facilitate the use of standard-
length ERCP accessories (140, 142) . The 2.8 mm-working channel limits the use 
of some appliances, e.g. SEMS. In addition, there are cases where the short DBE 
is unable to reach the target site, whereas a long DBE may be more efficient. In 
a retrospective, single-center report, Itokawa et al. found a statistically significant 
difference in insertion success rate between standard long and short balloon-assisted 
enteroscopy (89% vs. 50%) in HJ patients with Roux- en-Y reconstruction (141) . 
After the Whipple procedure, the corresponding figures were 94% and 92%, with 
no significant difference. Recently Sakakihara et al. reported retrospective results 
of short DBE therapy on strictures of the choledochojejunal anastomosis in 44 
patients. Cannulation was successful in 36 cases. If the dilator balloon was fully 
inflated (5 atmospheres) within 60 seconds they received dilation therapy only 
(n=19), otherwise treatment consisted of dilation and stent therapy (n=17). The 
stents used were 5–7Fr plastic stents. Whether single or multiple stenting was used 
was not disclosed. The stents were changed every 3–6 months until the stricture 
had resolved, defined by contrast material running out freely within 30–60 seconds. 
These patients needed up to six stenting (and therefore DBE) episodes (mean 3.1). 
Four of the stented strictures did not resolve, still having stents at the end of the 
observation period. There was a recurrence rate of 26% in the dilation group and 15% 
in the dilation and stent group during follow-up. These were successfully retreated 
with the same protocol as initially and no further recurrences were found by the 
end of the observation period (139) .
2.6.4  WORKING CHANNEL OF BALLOON ENTEROSCOPES
A thin working channel (2.8 mm) limits the use of accessories available. In 2014, 
Kawashima et al. reported a significant time difference in instrument insertion 
comparing a 168-cm-long DBE with a 2.8-mm working channel with a prototype 
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SBE (SIF-Y0004-V01; Olympus Medical Systems, Tokyo, Japan) of the same length 
with a 3.2-mm working channel, suggesting that channel width affects procedure 
time as well (148) . The same type of endoscope (model SIF-Y0004; Olympus 
Medical Systems, Tokyo, Japan), specially developed for ERCP use, was used in a 
report of Yamauchi et al. in 2014, considering ERCP in surgically altered anatomy 
with various indications in 22 patients. None of these patients had, however, BBS . 
Four patients had cSEMS inserted; the indications for these stents were not disclosed 
in the paper (149) .
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3. AIMS OF THE STUDY
Endoscopic stent therapy for extrahepatic biliary strictures was evaluated. Individual 
aims of the studies were as follows:
I. To analyze the therapy outcome of biliary strictures or leaks occurring after 
LT when managed with removable partially or fully covered self-expandable 
metallic stents.
II. To compare surgical outcomes in PD or TP patients with preoperative 
biliary drainage with either plastic or self-expandable metallic stents, with a 
supplementary analysis of operated patients without preoperative endoscopic 
stenting.
III. To compare the feasibility and safety of removable fully covered metallic stents 
with multiple plastic stents in the therapy for CP-induced biliary strictures.
IV. To describe the equipment and technique used in endoscopic benign bile duct 
stenting with cSEMS in patients with surgically altered anatomy, a technique 
that has not previously been possible/described.
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4. MATERIALS AND METHODS
The study was carried out at Helsinki University Hospital, Department of 
Gastrointestinal Surgery (reorganized into Helsinki University Hospital Abdominal 
Center since January 2015). Studies I, II, and IV were retrospective in nature, 
requiring no approval by the ethics board. The prospective research of this thesis 
(III) was approved by the local ethics committee and registered at ClinicalTrials.
gov with the identifier NCT01085747.
All patients in Studies I and IV were treated at the Unit of Therapeutic Endoscopy 
of Meilahti Hospital at Helsinki University Hospital, as were the majority of the 
patients in Studies II and III. However, 27 (14%) of 191 preoperatively, endoscopically 
stented patients in Study II were stented at other hospitals, as were 12 (20%) of 60 
patients in the multicenter study (III).
All patients were consciously sedated for the ERCP procedures by an 
anesthesiologist.
The definitions and gradings of ERCP-related complications were based on 
consensus criteria (150) .
4.1  STUDY I
Between March 2008 and May 2010, 17 liver-transplanted patients with a CC-
anastomosis and an anastomotic bile complication (16 strictures, 1 leak) received 
a cSEMS. Five patients had previously received a single, diagnostic NEPS. Data 
were retrospectively collected from patient charts and cholangiograms. The study 
is of a descriptive nature.
ERCP technique and equipment used. The papilla was cannulated using a 
sphincterotome with a guidewire. Patients with a native papilla had sphincterotomy. 
The anastomotic leak or stricture was identified and measured on fluoroscopy using 
a guidewire balloon and contrast media. All but one patient were stented with an 
Allium™ stent (Allium Medical Solutions Ltd, Caesarea Ind. Park, Caesarea, Israel) 
made of a super-elastic nitinol with a polymeric material cover. The anchored model 
of the stent was used in all cases but one. The stents expanded to a 10-mm diameter 
and were 6, 8, or 10 cm long. Three Allium™-stented patients initially received a 6- to 
8-cm-long partly covered Wallstent™ (Boston Scientific Corp., Boston, MA, USA), 
as fully covered stents were not yet available at that time. Two patients were stented 
with a custom-made, fully covered Micro-Tech stent (Micro-Tech, Nanjing, China), 
one of whom initially had an Allium™ stent. These stents were 3 and 4 cm long and 
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chosen in order to obtain experience of short stents in the current indication. The 
stents, except for the Wallstents™, were placed entirely inside the CBD.
Biliary cSEMS had not previously been used in CC-AS at our unit and experience 
worldwide in their use was scarce. The optimal or even maximal indwelling time 
was not known. Therefore several patients, mainly at the beginning of the study, 
had a premeditated stent exchange 3–4 months from deployment.
Follow-up. The patients were clinically evaluated at routine post-LT control visits 
or, if needed, at additional check-ups.
Table 3. Patient characteristics (I).
Number of patients 17
Gender: M/F (%) 7/10 (41/59)
Age (years) at first stent placement: median (range) 40 (18–61)
Received liver, n:
- cadaveric reduced size
- cadaveric full size
1
16
Indication for LT, n (%):
- acute or subacute liver failure
- alcohol cirrhosis
- Wilson’s disease
















M: male, F: female, LT: liver transplantation, PBC: primary biliary cirrhosis, 
PSC: primary sclerosing cholangitis
1 The patient had a re-transplant due to chronic rejection.
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Figure 3. Illustration of the stents used (I).
4.2  STUDY II
The surgical databases of Helsinki University Hospital searched for patients having 
had PD or TP during 2000–2009, yielded 366 patients. Of these 191 patients had 
endoscopic PBD and nine patients preoperative PTC. The endoscopically stented 
patients were divided into NEPS and SEMS groups and the unstented patients 
were grouped as patients with (UBO) or without (UNO) biliary obstruction. Patient 
characteristics and other variables were collected from patient charts and gathered 
in a Microsoft Windows Access™ database. The NEPS used were 10 Fr in diameter 
and 4–7 cm long. The metallic stents used were both covered (n=10) and uncovered 
(n=18) and 4–8 cm long, expanding to a diameter of 10 mm. The choice between 
covered and uncovered stents was based on the endoscopist´s occasional preference.
Bacterial culture results on intraoperative bile duct juice samples were obtained 
for 156 cases; 141 were preoperatively stented patients, seven belonged to the UBO 













4. MATERIALS AND METHODS
Table 4. Patient characteristics of stented cases (II).
Stented at ERCP Total (n=191) NEPS (n=163) SEMS (n=28)
Median Min Max Median Min Max Median Min Max
Age (years) 64 35 82 64 36 82 64 52 79
Stricture length (cm) 2 0 6 2 0 6 2 0.5 4.5
CCI 0 0 6 0 0 6 0 0 5
ASA status (I–IV) 2 1 4 2 1 4 2.5 1 3
Pre-stent bilirubin (umol/l) 201 7 671 205 7 645 202 16 671
Preoperative bilirubin (umol/l) 21 3 460 21 3 460 31 5 414
CCI= Charlson comorbodity Index, ASA= American Society of Anesthesiologists´ Physical Status 
Classification
Table 5. Patient characteristics of unstented cases (II).
PTC-drained and 
unstented
Total (n=175) PTD (n=9) UBO (n=9) UNO (n=157)
Median Min Max Median Min Max Median Min Max Median Min Max
Age (years) 61 25 83 66 57 74 65 31 75 60 29 78
CCI 0 0 9 2 0 5 0 0 0 0 0 9
ASA status (I–IV) 3 1 4 4 3 4 3 2 4 3 1 4
Preoperative 
bilirubin (μmol/l) 9 2 511 20 8 293 334 129 511 8 2 153
CCI= Charlson comorbodity Index, ASA= American Society of Anesthesiologists´ Physical Status 
Classification
4.3  STUDY III
In a prospective, randomized, multicenter study, 60 consecutive patients with BBS 
caused by CP were stented by ERCP at Helsinki (n=48), Oulu (n=6) and Turku 
(n=6) University Hospitals. The patients were randomized using sealed envelopes 
between April 2008 and September 2012. All patients gave their informed consent.
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Table 6. Patient characteristics (III).
Total (n=60) NEPS (n=30) fcSEMS (n=30) p-value
Male/female, n (male in %) 54/6 (90) 29/1 (97) 25/5 (83) 0.195
Age, years ; median (range) 53 (33–78) 49.5 (30–69) 54.5 (30–78) 0.160




























Pancreatic calcifications, n 46 23 23 1.000
Gallbladder not removed, n (%) 48 (80) 23 (77) 25 (83) 1.000
Stricture length, cm;  
median (range)
3.0 (1.0–5.2) 2.5 (1.0–5.0) 3.0 (1.0–5.2) 0.436
Maximum diameter of the CBD 
above the stricture, mm; median 
(range)





46 (5–275) 31 (7–244) 72 (5–275) 0.083
Initial AFOS; median (range)
(35–105 U/l)
393 (50–1767) 320 (50–1040) 487 (86–1767) 0.111
NEPS, non-expandable plastic stent; fcSEMS, fully covered self-expandable stent; CP, chronic 
pancreatitis; CBD, common bile duct; AFOS, alkaline phosphatase
The initial ERCP was performed if biliary obstruction caused by CP was suspected 
based on elevated bilirubin and/or AFOS levels. All patients received a single NEPS 
after sphincterotomy. Clinical and laboratory findings were recorded at the time.
Randomization into NEPS or cSEMS groups occurred at the second ERCP 1–3 
months later.
The cSEMS used were Hanarostent™, Wallflex™, and Wallstent™. The NEPS 
were progressively increased during the ERCPs, aiming at a total of six stents.
4.4  STUDY IV
Three patients with surgically altered anatomy were endoscopically stented with 
cSEMS. Endoscopic deployment of SEMS in patients with altered anatomy has not 
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previously been described in the literature. Therefore the partly novel equipment 
and management techniques are described in detail below.
Patient 1 was a 73-year-old male with previous Billroth II-type gastric resection. 
In January 2014 the patient developed cholecystitis complicated by a subphrenic 
abscess, which was drained, and the patient received antibiotics. As a bilioenteric 
fistula was suspected, a DBE ERC was performed. Even though the papilla was 
reached, the CBD could not be cannulated. Fluoroscopy showed air in the biliary 
tree, strengthening the suspicion of a bilioenteric fistula. Thus, and also due to 
established cholecystitis, in May 2014, the patient had an open cholecystectomy, 
during which a T-tube was placed in the CBD. A distal stricture of the CBD was 
seen on cholangiography one week later and DBE ERC was re-attempted.
Patient 2 was a 57-year-old female with Crohn´s disease and PSC. She received 
a LT with a HJ reconstruction in 1998. During the summer of 2013 the patient 
suffered from recurrent cholangitis episodes, requiring treatment with antibiotics. In 
October 2013, a short stricture of the HJ and slightly dilated intrahepatic bile ducts 
in segments II and III of the liver were discovered on contrast-enhanced MRI. A 
prophylactic antibiotic was administered. As the changes persisted six months later 
and biopsy showed stage I fibrosis along with cholangitis raising a suspicion of PSC 
relapse, PTC was performed. The PTC drainage did not work sufficiently despite 
several drain changes, and thus, a rendezvous procedure using DBE was attempted.
Patient 3 was a 72-year-old female with a previous pancreaticoduodenectomy in 
August 2013 due to T2N1 neuroendocrine tumor in the head of the pancreas. The 
patient suffered from relapsing cholangitis episodes, suspected to be caused by 
stricture of the HJ anastomosis. 
4.4.1  EQUIPMENT AND THE PROCEDURES IN DETAIL
A Fujifilm DBE (model EN-450T) with a 200-cm working length and a 2.8-mm 
working channel (Fujifilm Corp., Tokyo, Japan) was used during the procedures 
in Patient 1 and 2. In Patient 3, a Fujifilm DBE (model EN-580T) with a 200-cm 
working length and a 3.2-mm working channel (Fujifilm Corp.) was employed. 
A 145-cm-long and 13.2-mm-wide TS-13140 overtube with a transparent hood 
attached to the tip of the scope was employed in all three cases. During the procedure 
all patients were in prone position and under conscious sedation controlled by an 
anesthesiologist and a nurse. CO2 insufflation was used in all procedures. The wires, 
catheters, and stents for the individual cases are presented separately hereafter.
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Case 1. In June 2014, the DBE was intubated to the papillary area. Through the 
T-tube, a guidewire (HydroSteer™; St. Jude Medical, Minnetonka, MN, USA) 
was inserted into the duodenum. With a balloon catheter (triple-lumen extraction 
balloon; Endo-Flex GmbH, Voerde, Germany) on the guidewire, a Jagwire™ 
(Boston Scientific, Alajuela,Costa Rica) was inserted through the T-tube into the 
duodenum and afterwards out of the mouth using a snare through the enteroscope. 
Through the mouth and over the Jagwire™ running alongside the enteroscope, 
under fluoroscopic and endoscopic control, an fcSEMS (4 cm long, 10mm diameter; 
Niti-S biliary covered stent [Kaffes™; TaeWoong Medical Co., Ltd., Gyeonggi-do, 
South Korea]; 9 Fr, 180 cm introducer) was inserted into the CBD. The T-tube 
was removed.
Case 2. When the DBE was intubated, the endoscope started looping in the distal 
part of the afferent jejunal limb, preventing the scope from proceeding. Therefore, 
a guidewire (Radifocus™ non-vascular angled guidewire, 0.035 inch diameter, 450 
cm long; Terumo Europe NV, Leuven, Belgium) was inserted through the PTC 
drain, to reach the enteroanastomosis. This was exchanged for a longer Jagwire™ 
(Boston Scientific). 
With the help of a cut Ramp catheter (Haber Ramp™ catheter; Cook Medical, 
Limerick, Ireland) a second Jagwire™ was inserted and then both wires were pulled 
out through the mouth with the enteroscope. The enteroscope was drawn to the HJ 
area on one of the wires and with help of the other, a 3-cm-long fcSEMS (Niti-S 
biliary covered stent [Kaffes™]; 9 Fr, 180 cm introducer) was inserted and released 
under fluoro- and endoscopic control, verifying that the stent snare reached the 
bowel. To ensure later access with the DBE, a clamped PTC drain was left inside 
the stent. Even though an indwelling time of one year was planned, a check-up 
procedure was booked 3 months later.
Case 3. During the DBE the HJ was discovered to be very narrow, barely bypassed 
with a guidewire (FTE-Wildcat; 0.035 inch diameter, 650 cm long; pk endoskopie 
GmbH, Hannover, Germany). A needle knife (FTE-B2- papillotome; 250 cm long, 
2.3/1.8mm diameter; pk endoskopie GmbH, Hannover, Germany) precut was 
performed and the anastomosis was dilated with a 10-mm dilation balloon (CRE 
wireguided dilatation catheter; 290 cm long; Boston Scientific, Natick, MA, USA). 
A custom-made 2-cm-long Hanaro fcSEMS, expanding to 10mm (Hanarostent™ 
fully covered biliary flap; 9 Fr, 230 cm long delivery device; M.I. Tech Co. Ltd., 
Gyeonggi-do) with antimigration flaps was deployed through the DBE working 
channel. To assess whether the stent had migrated or not, a plain abdominal X-ray 
was planned at 6 and 12 months from the procedure.
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Figure 4. Fujifilm double balloon endoscope, model EN-580T, with a 200-cm working length and 
a 3.2-mm working channel (Fujifilm Corp.).
4.5  CLASSIFICATIONS, GRADINGS AND SCORES
The ASA classification was used to characterize patients´ physical health and the 
Charlson Comorbidity Index (CCI) with regard to certain pulmonary, cardiovascular, 
cancer and internal organ states was used to describe concomitant diseases (II). 
Postoperative pancreatic fistulas were graded according to the International Study 
Group of Pancreatic Fistula (ISGPF) classification into grades A, B, and C (II). 
Grade A fistulas are asymptomatic and transient chemical fistulas, not requiring 
further interventions. Grade B fistulas require minor therapeutic actions, e.g. 
endoscopic management, in symptomatic but otherwise stable patients. Patients 
with severe, clinically significant grade C fistulas appear unstable and ill, needing 
major therapeutic interventions.
To describe and quantify the bacterial cultures from the bile samples taken during 
the operation, a bacterial score was created (II). This score ignores the virulence of 
the microbes, considering only the number and amount of bacterial strains.
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I. Bacterial strains Points
no growth 0
one strain 1
two different strains 2
n          ’’               ’’ n










Bacterial score = I + II + . + …+ N.
Figure 5. Illustration of how the bacterial score was calculated (II).
4.6  STATISTICAL ANALYSES
The calculations for statistical analyses in Studies II and III were performed using 
IBM SPSS™ (Statistical Package for the Social Sciences; v20, IBM Corp., Armonk, 
NY, USA), StatXact™ (v4.0.1, Cytel Software Corp., Cambridge, MA, USA) and in 
Study III alone Egret™ (v2.0.31, Cytel Software Corp.).
For the prospective study (III), sample size calculations were based on previous, 
non-randomized reports of BBS treatment in CP, with 90% treatment success 
using cSEMS compared with 60% success using NEPS. The parameters used for 
calculation were power= 0.8; α= 0.05, giving a sample size of 60 patients (30+30).
Data are presented as median and range (I, II, III) or number of patients and 
percentage (I, II, III). The Kolmogorov-Smirnov test was used to test distribution 
normality for continuous data (II, III). Comparison of normally distributed 
continuous data was performed with Student´s t-test and non-normally distributed 
continuous data with the Mann-Whitney U-test (II, III) or the Kruskal-Wallis test 
(II). To ascertain significant correlations between continuous data, the Spearman 
correlation coefficient was calculated (II). Hodges-Lehman median differences were 
calculated with 95% CI to assess differences in medians (III). Fischer´s exact test 
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(II, III) or the Fisher-Freeman-Halton test (II) was used to determine differences in 
categorical variables, and the linear-association test was used to test trends in ordinal 
variables (II). For proportions, the exact Clopper-Pearsons confidence intervals were 
calculated (II, III). The Kaplan-Meier method was used for time-to-event analysis, 
and the differences between groups were assessed using the Log-Rank test (III). Two-
sided p-values were used, and p-values <0.05 were considered significant (II, III). 
For multiple testing, the p-values were corrected using the Bonferroni method (II).
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5. RESULTS
5.1  STUDY I
5.1.1  ERCP, STENT THERAPY AND OUTCOME
Of the 17 patients with post-LT biliary strictures or leaks treated with cSEMS, two 
(12%) had a recurrence. The patients with recurrences were re-stented resulting in 
eventual stricture or leakage resolution in all patients. The total number of ERCPs 
performed was 58. The median number of procedures in each treatment entity 
(n=19) was three (2–6), with cSEMS deployment in 29. Balloon dilation to 6, 8, 
or 10 mm preceding stent placement was performed 19 times. There were seven 
procedures to check the stent and two planned ERCPs to ensure that the stricture had 
not recurred. Six patients (35%) had a stent exchange 3–4 months from placement, 
whereas eight (47%) were treated with only one stent. After stent therapy, decreased 
liver function tests were seen in all patients.
The one leakage patient received a second stent put partly inside the first one as 
the leakage continued. Even though the leakage resolved, the patient had repeated 
episodes of cholangitis, which were regarded as resulting from multiple ischemic 
hilar and intrahepatic strictures, leading to a retransplantation after several attempts 
of endoscopic therapy with NEPS.
Figure 6. ERCP pictures of an anastomotic stricture in a 56-year-old male, six weeks after liver transplantation, 
before and after stenting with an Allium™ stent (I).
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5.1.2  STENTING TIME AND FOLLOW-UP
The median stenting time was 6.8 months (0.9–10.1). The longest indwelling time 
for a single stent was 9 months, and it was taken out without difficulty. During 
follow-up, which was 21.7 months (6.6–32.0) after stent removal, the liver function 
tests remained at the level achieved.

















1 2x Allium™ 4 10.1 Anchor snap 32.0
2  Wallstent™
Allium™
4 9.9 1st stent migrated 29.4
3 – 1st Allium™ 2 0.9 1.4
3 – 2nd Allium™ 3 3.2 22.4
4 Wallstent™
2x Allium™
6 9.7 1st stent migrated 
below the stricture
26.0
5 Allium™ 2 4.2 20.9
6 2x Allium™ 3 9.7 28.5
7 – 1st 2x Wallstent™ 3 4.2 2.1 1st stent migrated 
inside the CBD
7 – 2nd 2x Allium™ 3 6.1 Cholangitis 28.7
8 Allium™ 2 5 29.6
9 Allium™ 3 6.7 Stent coming out in 
pieces + cholangitis
11.5
10 Allium™ 2 9 21.7 
11 2x Allium™ 4 9 11.4
12 Allium™
Micro-Tech
3 8.2 1st stent migrated 
below the stricture + 
anchor snap
25.9
13 2x Allium™ 3 2.3 Cholangitis x2 8.7
14 Allium™ 3 6.8 11.3
15 Allium™, 
unanchored
2 3.2 Mild pancreatitis + 
cholangitis
13.8
16 Micro-Tech 3 4.4 10.7
17  Allium™ 3 6.8 Haemathemesis 6.6
Mo = months, CBD = common bile duct
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5.1.3  COMPLICATIONS AND DRAWBACKS
There were four stent migrations (24%), three of which occurred when a Wallstent™ 
was used, giving a 100% migration rate for Wallstent™. One of these was not detected 
on abdominal fluoroscopy during ERCP, indicating a complete migration. The fourth 
migrated stent, which had migrated just below the stricture, was an Allium™ stent, 
giving a 4% (n=1/23) migration rate for this stent type. It was replaced by a custom-
made Micro-Tech stent. Two recurrences were seen, one following the treatment 
with a Wallstent™, the other after using an Allium™ stent.
There were complications connected to nine ERCP procedures (16 %). Cholangitis 
was seen five times (9%). The anchor of the Allium™ stent was broken off twice, 
without affecting the ability to remove the stent. One Allium™ stent was unravelled 
into metal filaments during removal, leaving the cover in the CBD. A FlowerBasket™ 
device (Olympus Medical Systems Tokyo, Japan) was used to remove the cover. 
This patient had postprocedural cholangitis and bacteremia, successfully treated 
with antibiotics. The indwelling time for this stent was six months. One patient 
(1.7%) developed PEP. This patient had concomitant cholangitis, and the PEP 
was deemed mild, alhough the hospital stay was markedly prolonged since the 
cholangitis was treated with intravenous antibiotics. One procedure was complicated 
with hematemesis two days after stent deployment. During a duodenoscopy a red 
spot found at the sphincterotomy was treated with a heat probe. No deaths occurred.
5.2  STUDY II
5.2.1  PRIMARY ENDPOINT: STENT FAILURE RATE
Initially, 168 (88%) of the 191 stented patients had a plastic stent. One was exchanged 
due to stent migration and twelve due to dysfunction. At the exchange, five patients 
received a SEMS. One cSEMS partially migrated towards the duodenum, resulting in 
dysfunction and stent exchange to a uSEMS. This resulted in 176 NEPS placements 
and 29 SEMS placements, giving a stent failure rate of 7.4% (95% CI: 4.0–12.3%) 
in the plastic group and 3.4% (95% CI: 0.1–17.7%) in the SEMS group, (p  = 0.697, 
difference: −3.5%, 95% CI: −16.6–12.9%).
5.2.2  SECONDARY ENDPOINTS
The differences between the stent types regarding bilirubin levels, the bile juice 
bacterial level and postoperative complications were secondary endpoints of the 
study. The patients were arranged into groups according to their final preoperative 
stent type, resulting in 163 patients (85%) in the plastic group and 28 in the SEMS 
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group. The analyses were extended to comprise PD and TP patients having had 
preoperative PTD for biliary obstruction (n=9) and unstented patients with (UBO, 
n=9) or without (UNO, n=157) biliary obstruction.
5.2.2.1  Tumor size and neoadjuvant therapy
When comparing NEPS and SEMS stented patients, no difference was present in 
tumor size (p= 0.931).
Twenty-five endoscopically stented patients (13%) had neoadjuvant therapy. The 
majority of them (n=22) had a NEPS. None of those receiving neoadjuvants needed 
stent exchange or additional ERCP procedures before surgery. The median time 
from stenting to surgery was 34 (3–102) days in the patients without neoadjuvant 
therapy and 110 (20–266) days in those receiving neoadjuvant therapy.
5.2.2.2  Bilirubin levels
Neither bilirirubin levels before stenting (p=0.732) nor preoperative levels (p=0.157) 
showed a difference between the stent groups. There were 171 patients with 
documented bilirubins both before stent placement and prior to surgery. Before 
stenting, 149 patients (126 with NEPS, 23 with SEMS) had a bilirubin level exceeding 
50 μmol/l. In the NEPS group 45% of patients reached a preoperative level of 20 
μmol/l or less. The corresponding figure in the SEMS group was 26% (p=0.110). 
Eighty percent of patients in the NEPS group and 61% in the SEMS group had a 
preoperative level below 50 μmol/l (p=0.058).
The preoperative bilirubin level was higher than that before ERCP in four NEPS 
patients and one SEMS patients. This could be described as a functional stent failure 
rate, which was 2.5% in the NEPS and 3.6% in the SEMS group, with no significant 
difference in the distribution between the groups (p=0.551).
5.2.2.3  Bacterial scores of bile juice samples
The intraoperatively obtained bile juice samples had a median bacterial score of 
6 (0–23), with a median score of 6 (0–23) in the NEPS group and 6 (1–14) in the 
SEMS group. The mean difference in the score was 0.41 (95% CI -1.24–2.06). Of the 
stented patients only one (with a NEPS) had sterile bile, whereas all seven cases with 
documented bile samples among the unstented patients with biliary obstruction had 
sterile bile. The unstented patients without bile obstruction had sterile bile in 73% 
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of cases; the corresponding figure for PTD patients was 11%. When the proportion 
of sterile bile juices in unstented patients with biliary obstruction (100%; n= 7/7) 
was compared with that in stented patients (1%; n=1/155), a statistically significant 
difference emerged (p<0.001). However, the groups were of very different sizes.
Figure 7. Graphic presentation of the correlation between the bilirubin level and time from stent placement 
to operation. The bilirubin level decreases as the time from stent placement increases.
5.2.2.4  Infection complications
Infection complications arose in 28 endoscopically stented patients (15%). The 
complications were wound infections, including two at the origin of the vein 
graft (n=9), urinary tract infection (n=8), bacteremia (n=5), pneumonia (n=4), 
clostridium colitis (n=2), and intra-abdominal abscess (n=1). When the NEPS and 
SEMS groups were compared, no significant difference emerged (p=0.057), as was 




5.2.2.5  Postoperative pancreatic fistulas
There were 183 PD patients with an endoscopically deployed stent. Twenty-six (14%) 
of these patients had a postoperative pancreatic fistula. No significant difference was 
seen in the distribution of fistulas between the NEPS and SEMS groups (p=0.072). 
Even though SEMS patients had no Grade A fistulas and there were 18 (12%) in 
the NEPS group, the difference between the groups was not significant (p=0.238). 
Nor was there a significant difference in the occurrence of fistulas when the stented 
patients were compared with the UBO group (p= 1.000). In the endoscopically 
stented patients, no difference was observed in the distribution of the bacterial score 
regarding the different categories of fistulas (p=0.596). Nor was there a difference 
between the NEPS and SEMS groups when patients having a postoperative infection 
complication and/or a fistula were compared. There were 49 such patients, 42 (26%) 
in the NEPS and seven (25%) in the SEMS group (p=1.000).











Tumor size, median (range), mm 30 (5–150) 30 (7–150) 30 (23–35) 34 (13–70) 32 (9–140)


























Bacterial score, median (range) 6 (0–23) 6 (1–14) 6 (0–16) 0 (0–0) 0 (0-19)
Postoperative infection 
complications, n (%)




















Reoperations, n (%) 6 (4) 3 (11) 0 (0) 0 (0) 13 (8)
NEPS= patients with non-expandable plastic stent; patients with SEMS= patients with self-
expandable plastic stent; PTD = patients with percutaneous transhepatic biliary drainage; UBO 
= unstented patients with biliary obstruction; UNO = unstented patients with no biliary obstruction
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5.2.2.6  Reoperations
There was no difference between the NEPS and SEMS groups regarding the 
number of reoperations with indications other than Grade C fistulas (p=0.129). 
The indications were leakage of the HJ (n  = 3), bleeding (n  = 2), mechanic stomach 
retention (n  = 1), suspicion of necrotizing fascitis (n  = 1), peritonitis caused by slip of 
the drain into the abdominal cavity (n  = 1), and thoracotomy due to massive bleeding 
after drainage of pleural fluid (n  = 1).  Of the patients with a HJ leak, two were 
stented with a NEPS and one with a cSEMS. When endoscopically stented (n=9/191, 
5%) and unstented (n=13/166, 8%) patients were compared for reoperations, no 
significant difference emerged (p=1.000).
5.2.2.7  Postoperative hospital stay and mortality
The median postoperative hospital stay was 11 (6–112) days in the NEPS and 
12 (8–50) days in the SEMS group; thus no significant difference was present 
between the groups (p=0.750). Both the unstented and stented patients had a 30-
day postoperative mortality rate of 0%.
5.2.2.8  ERCP-related complications
The number of complications related to ERCP and biliary stenting was nine (4.7%). 
Two patients (1.0%) had post-ERCP bleeding. These were managed conservatively, 
even though the other patient had a duodenoscopy when the bleeding had already 
stopped. Seven cases of mild PEP (3.4%) were seen. There were no cases of severe 
PEP, perforations or procedure-related cholangitis.
5.3  STUDY III
Of the randomized patients, two dropped out before the stents were removed. This 
resulted in a final sample size of 30 patients in the NEPS group and 28 patients in the 
SEMS group when the follow-up started. One non-compliant patient did not show 
up for the third ERCP, and thus, he ended up with only three NEPS. The remaining 
patients received four (n=1), five (n=5), and six (n=23) stents. When comparing 
the total ERCP durations between the groups, the durations in the cSEMS groups 
were significantly shorter (p=0.008).
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Figure 8. Multiple plastic stents across the papilla.
5.3.1  STENT REMOVAL
There were difficulties in removing four cSEMS in the early stages of the study. Two 
stents were discovered to be broken before they were removed. One of them was 
completely removed, the other only partially. The remnant remains in the patients 
CBD and has not caused problems during follow-up. One stent broke into two 
parts when removed. The other part was removed during another ERCP procedure 
with cholangitis as a consequence. When first attempted, a Wallstent™ could not 
be removed, needing successive ERCPs with placement of another cSEMS in the 
original one, until both stents eventually were removed.
5.3.2  FOLLOW-UP AND RECURRENCES
The median follow-up (April 2014), including the patients with recurrence, was 37 
(3–61) months in the NEPS group, 41 (1–66) months in the cSEMS group, and 40 
(1–66) months in all patients (p=0.832).
At the initial and last ERCP, the strictures and CBD diameters above the strictures 
were measured. The bilirubin and AFOS levels were measured before stenting and at 
the follow-ups at 6 and 24 months after stent removal. Two years from stent removal 
88% (n= 36/41) of the patients had a bilirubin level of 20 μmol/l or less and 98% 
(n=40/41) a level below 25μmol/l. There were no signs of CBD obstruction on US 
in the patients with values exceeding the normal limits. Findings indicating liver 
cirrhosis were seen at US of the patient with the highest bilirubin level (59 μmol/l).
There were five recurrences during the 2-year follow-up. Three of these were in 
the NEPS group and two in the cSEMS group. The success rates for the groups were 
88% (n=22/25; 95%CI 69–97%) and 91% (n=20/22; 95%CI 71–99%), respectively 
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Figure 10. Chart showing the study course and its 
results.1 One patient died of pancreatic cancer 4 
months after randomization, two had surgery for 
suspicion of pancreatic malignancy between ERCP 
III and IV or at the time of ERCP IV. 2Both died of 
causes unrelated to stent therapy. 3One patient had 
surgery because of suspicion of malignancy shortly 
after ERCP IV, and one died of unknown cause 5 
months after stent removal.
Figure 9. ERCP pictures of a male with chronic 
pancreatitis and biliary stricture before stenting, 
after the stent was deployed and after stent retrieval. 
The red arrows point at the ends of the cSEMS and 
the black arrow at a pancreatic plastic stent.
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demand only, no scheduled 
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Figure 10. Chart showing the study course and its results. 1One patient died of pancreatic cancer 4 
months after randomization, two had surgery for suspicion of pancreatic malignancy between 
ERCP III and IV or at the time of ERCP IV. 2Both died of causes unrelated to stent therapy. 3One 
patient had surgery because of suspicion of malignancy shortly after ERCP IV, and one died of 
unknown cause 5 months after stent removal. 
NEPS≈ non-expandable plastic stent; cSEMS= covered self-expandable metallic stent 
NEPS=non-expandable plastic stent; cSEMS= covered self-expandable metallic stent
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(P=1.000), with an overall success rate of 89% (42/47; 95%CI 77–96%). The patients 
were advised to contact the hospital in cases of symptoms or adverse events after 
the 2-year follow-up as well, resulting in further time-to-event data. Regarding 
this analysis, the success rates for were 90% (95%CI 72–97%) and 92% (95%CI 
70–98%), respectively (p=0.405). Additionally, one patient in the NEPS group had 
a late stricture 50 months after the stent was removed, diminishing the success rate 
for plastic stents to 72% (95%CI 27–92%).
Figure 11. Time-to-event analysis of recurrences of CP-induced biliary strictures managed by stents. The 
figure shows time passed from stent removal to observation of recurrent stricture (each step indicates 
one patient with stricture recurrence) in patients treated with multiple plastic stents or a single covered 
self-expandable metallic stent (cSEMS) for 6 months (III).
5.3.3  COMPLICATIONS AND ADVERSE EVENTS
Adverse events were found in seven patients (23%) in the NEPS group and eight 
patients (29%) in the cSEMS group (p=0.767). Two patients (7%) in the NEPS 
group and four (14%) in the cSEMS group had cholangitis (p=0.415). When the 
study started, 23 patients in the NEPS and 25 in the cSEMS group had an intact 
gallbladder. One patient from each group developed acute cholecystitis during stent 
therapy. The groups had three (10%) and two (7%) occasions of stent migration, 
respectively (p=1.000). The plastic stents migrated proximally twice, and once into 
the duodenum. The cSEMS migrations (one proximal and one distal), observed at 
the third ERCP 3 months after stent deployment, were re-stented.
In the NEPS group two patients had pseudocyst infection and one patient´s 
pancreatic stent had migrated and perforated the transverse colon through the 
duodenum during the follow-up, forming additional adverse events. Other adverse 
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events in the cSEMS group were one pseudocyst bleeding and one duodenal 
obstruction. These were thought to be unrelated to biliary stent therapy.
There was one case of mild PEP. As the total number of ERCPs was over 200, 
the PEP rate was 0.5%.
5.4  STUDY IV
Case 1.  The fcSEMS was successfully deployed. A DBE ERC for stent removal was 
set up 6 months later. Before the scheduled procedure, the patient presented with a 
subcutaneous abscess at the operation wound scar in October 2014. On CT scan it 
communicated with a deeper 6 x 2 x 1.5 cm abscess located between the diaphragm 
and left liver lobe. The fcSEMS was in place and open. The abscess was successfully 
drained. One month later, the abscess had recurred. There was no communication 
with the biliary tree on CT fistulography, but the bile ducts in the left lobe were 
dilated. The liver function test and bilirubin levels were low.
The liver surgeons were consulted because of the persistent abscess. At the 
time the CT scan revealed a portal thrombosis. The abscess seemed to resolve 
conservatively when treated with antibiotics. As pus discharge through a skin 
opening persisted and the patient had recurrent episodes of fever, sanitizing surgery 
was scheduled. A laparotomy was performed in April 2015, revealing that the fistula 
was connected to the hilar site.  Affected were liver segments II and III, revealed 
by peroperative cholangiography, and these segments were resected along with a 
part of segment IV.
The patient recovered well from surgery. The CT scan in August 2015 revealed 
no signs of leakage or abscess residue. The stent and biliary tree contained air as a 
sign of stent patency. Clinical follow up in October 2015 revealed normal laboratory 
findings and clinical recovery.
In December 2015, the patient presented with upper abdominal pain, fever, and 
elevated AFOS and bilirubin levels. The CT scan revealed no air in the biliary tree 
as a sign of stent occlusion and, surprisingly, a pancreatic tumor with multiple lung 
metastases. A DBE ERC was performed, showing an occluded cSEMS, which was 
removed. The patient was referred for palliative oncologic treatments.
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Figure 12. Endoscopic view of the incrusted cSEMS in Case 1 before removal. The removal of the stent by 
pulling a snare is seen on fluoroscopy. 
Case 2. In the DBE ERC three months after deployment, migration of the previously 
successfully deployed fcSEMS was observed. The stent had migrated above the 
anastomosis into a bile duct.  A 13-mm balloon (triple-lumen extraction balloon, 
250cm long; Endo-Flex GmbH) was passed through the anastomosis without 
difficulty and the stent was removed. The stent was not replaced as the HJ was 
well open, and the PTC drain was removed. 
One year later, the patient had a scheduled post-LT follow-up. She had had 
episodes of fever with upper abdominal pain monthly, which presumably were 
episodes of cholangitis.  A MRCP was performed, showing an obvious stricture 
in a right central biliary branch with concomitant intrahepatic bile duct dilation. 
Similar minor and more diffuse findings were made in the left liver lobe. There 
was also contrast enhancement of the bile duct walls as a sign of cholangitis. As the 
patient´s symptoms were transient and mild, the liver surgeons decided to treat 
the episodes with antibiotics for a short time. If the situation becomes worse DBE 
ERC will be considered.
Case 3. The fcSEMS was successfully deployed through the DBE channel. A follow-
up including plain abdominal X-ray was set up 12 months later to determine whether 
or not the stent had migrated. If migration had not occurred at that time, removal 
using DBE ERC would be scheduled.
As the stent was in place on the X-ray, DBE ERC was performed and the stent 
was removed without difficulty.
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Figure 13. Deployment of the cSEMS in Case 2, and fluoro- and endoscopic view before stent removal.
Figure 14. Endoscopic view of the very narrow HJ in Case 3 before and after precut and dilation.
Figure 15. Endoscopic and fluoroscopic view of the deployed cSEMS in Case 3.
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6. DISCUSSION
Endoscopic management of extrahepatic biliary strictures comprises numerous 
therapy approaches.  Aspects to be considered before therapeutic ERCP include 
benign versus malignant stricture, length and location of the stricture, whether 
the stricture tissue is smooth or firm, and etiology of the stricture, among others. 
Furthermore, the management of malignant strictures can be palliative, preoperative 
or either of these in borderline resectable pancreatic cancer, the approach being 
determined after chemotherapy. Not only the properties of the stricture warrant 
consideration, but whether or not to stent must be decided. If stenting is needed, 
a choice between countless different stents with various properties must be made. 
6.1  STENT THERAPY IN ANASTOMOTIC BILIARY STRICTURES 
AND LEAKS AFTER LT (I)
The first reports of using pcSEMS in post-LT anastomotic strictures were published 
in 2006 (72) . The stents were left in the CBD without intention of retrieval, with 
surgery as a rescue procedure in case of stent dysfunction. Kahaleh et al. published a 
preliminary report on temporary placement of cSEMS in postoperative biliary leaks 
in 2007, and later, in 2008, a piloting study of cSEMS in various BBS including 16 
post-LT strictures, with promising results (18, 151) . Simultaneously, LT patients´ 
ERCPs were reorganized and centralized to our unit at Helsinki University Hospital 
and (f)cSEMS for post-LT anastomotic complications was brought into use.
At this point, the use of cSEMS in benign indications was experimental both 
generally and at our institution, with no detailed design for this kind of stent therapy. 
For this indication, we mainly used a fully covered Allium™ stent, but in the early 
course of the study, partially covered Wallstents™ were used if the Allium™ was 
not available. The outcomes therefore cannot be directly compared. Moreover, 
two custom-made stents were used to acquire experience with short stents. As 
the Allium™ stent, according to our earlier experience, was prone to migrate in 
transpapillary usage, we decided to proceed with intracholedochal deployment of 
the Allium™ and the custom-made Micro-Tech stents. Indeed, only one Allium™ 
stent (4%), coincidentally discovered at a scheduled ERCP, migrated right below 
the stricture.
One unclear issue was the stenting time. It was unknown for how long a stent 
could be in place and still be removed. The optimal stenting time for stricture 
resolution was also not known. Therefore, the majority of our patients had routine 
stent exchange 3–4 months after stent placement. As transplant surgery in Finland 
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is centralized to Helsinki University Hospital, some patients travelled a considerable 
distance. It was thus preferable to have the ERCP procedures for these patients 
at the time of otherwise scheduled appointments, even though the timing for the 
procedure was not in accordance with the endoscopist´s recommendation. This 
explains the various stenting times in our study. This practice also gave us valuable 
information on stent retrievability after an indwelling time longer than 4 months. 
The longest indwelling time for an individual stent, removed without difficulty, was 
9 months. On the other hand, there was unravelling of an Allium™ stent after 6 
months in situ, which indicates that factors other than indwelling time also have 
an impact on removability.
In 2010, Chaput et al. presented a prospective uncontrolled study, where post-LT 
strictures were stented with a pcSEMS for two months with a nearly 50% recurrence 
rate, indicating that this stenting time was a too short (152). In our material we 
had two recurrences, one after a stenting time of 4.2 months with two consecutive 
Wallstents™ and the other after only 0.9 months of stenting (stent removed due 
to clinical misjudgement) with an Allium™ stent. On the other hand, we had five 
patients with stenting times from 2.3 to 4.4 months without recurrences. In a 
RCT comparing fcSEMS with multiple NEPS, Kaffes et al. had a median stenting 
time of 3.8 (2.5–5.5) months and a 33% recurrence rate(48). Interestingly, none 
of these studies analyzed the recurrences with respect to the time passed from 
transplantation to stricture. Rajab et al. recently described a more conservative 
approach to postoperative biliary strictures, placing a single 10 Fr stent with or 
without preceding balloon dilation, showing an overall stricture resolution of 72% 
and in post-LT patients 78% (82) . The median time for stricture formation was 
0.7 months with an interquartile range (IQR) of 0.3–1.3 months in the successful 
group, compared with 1.9 (IQR 0.9–2.1) months in patients failing endoscopic 
treatment (p=0.07). If spontaneous resolution of early AS is true, these could be 
managed by one NEPS maintaining the biliary flow, instead of subjecting the CBD 
to pressure from cSEMS or multiple plastic stenting with, at least, a theoretical risk 
for de novo strictures in this delicate patient group.
Overall, the results for cSEMS therapy in this study were satisfactory, as all 
patients eventually reached stricture resolution. On the other hand, as the study 
lacks a control group, it is unknown whether the same number of ERCP procedures 
for each patient with balloon dilation alone would have produced similar results. 
The need for re-transplantation in the sole leakage patient with eventual multiple 
hilar and intrahepatic strictures was probably not preventable, although a theoretical 
pressure-induced ischemia caused by the cSEMS cannot be ruled out.
Previously, multiple progressive plastic stenting has efficiently been used for 
management of post-LT AS with resolution rates as high as 94%, clearly competing 
with the results of this study and consistent also with earlier success rates for cSEMS 
(19, 47, 63, 67, 70) . However, this kind of management lasts for one year, is laborious 
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considering the need for trimonthly ERCPs, adds to patient discomfort and is less 
cost-effective than management using cSEMS(48).
6.2  STENT THERAPY IN BILIARY STRICTURES CAUSED BY 
CHRONIC PANCREATITIS (III)
The therapy outcome for BBS caused by CP is poorer than for other etiologies, 
probably due to its fibrotic and frequently occurring calcifying nature, and therefore, 
surgery is a favored treatment option (51, 71, 84, 86) . At present, the recommended 
first-line treatment is temporary placement of multiple, plastic biliary stents for one 
year, but metallic stents have increasingly been brought into use (86) .
The current study is the first RCT comparing multiple plastic stent therapy 
and cSEMS stenting in BBS caused by chronic pancreatitis. When conceiving the 
study, based on previous reports in the literature, management using cSEMS was 
assumed to be superior to that of multiple plastic stent therapy (18, 89) . However, 
according to the results both methods are highly efficient and superiority for either 
group could not be shown. However, the 95%CIs for the success rates are fairly wide, 
indicating the possibility that one of the methods is in fact better than the other.
The intended number for achieved 10 Fr stents in the NEPS group was six. 
This quantity was chosen to achieve a similar CBD diameter in both groups. 
Geometrically, six 10 Fr NEPS placed in a circle with a seventh stent in the center 
fills a 10-mm tube. In real-life stenting, a complete fit is impossible, which is why 
six stents can be considered close enough. Moreover, the spaces between the stents 
are thought to maintain drainage if the stents are clogged.
When using cSEMS, a two-staged procedure with one ERCP for deployment and 
another for removal is sufficient. As progressive stenting in the NEPS group required 
three ERCPs, a check-up ERCP between deployment and removal was included in 
the study protocol to eliminate the bias caused by unequal number of procedures.
As was the case in the post-LT cSEMS study, the optimal duration of stents was 
unclear when conceiving the CP study as well. The durations in anecdotal reports 
on cSEMS in BBS have varied, usually, however, being approximately 3 months (18, 
19, 153) . On the other hand, progressive stenting with NEPS has typically lasted for 
one year, with the briefest stent duration being 6 months, as stent exchange and an 
incremental increase of stents are needed trimonthly (68, 88) . A 6-month duration 
was selected here, as at the time it was not known whether cSEMS coverage would 
remain intact for one year.
At present, it is known that cSEMS can be indwelled for up to one year, thus 
being an attractive option for stent therapy in CP. Six plastic stents require 2–3 
ERCP procedures to change and increase stents to achieve an equivalent diameter, 
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and later additional procedures are needed to change occluded stents if a one-year 
stenting time is warranted.
No cost analysis comparing these stent therapies was conducted. However, a 
well-grounded assumption is that in clinical practice with a two-staged deployment-
removal protocol for cSEMS the cost-structure would resemble that of the 
congruently studied post-LT patients in Kaffes´s et al (48).  When summing the 
cost for nine plastic stents with two insertion catheters and one dilation balloon, 
it at least equals the price of one cSEMS, even without considering  the cost of an 
additional ERCP procedure.
6.3  PREOPERATIVE BILIARY DRAINAGE (II)
Historically obstructive jaundice has been considered to impair physical health prior 
to PD sufficiently to warrant surgical relief of the bile duct obstruction, resulting in 
a two-staged operation (120, 125, 154) . Naturally, when less invasive approaches 
via PTC- and ERCP-drainage became available, there was a shift towards their use 
(125) . In recent years, the need for preoperative drainage has been questioned 
and actually the current opinion is somewhat against routine PBD (1, 3, 100, 
154) . The fundamental change in opinion came with a Dutch multicenter RCT 
published in 2010, showing a significantly lower risk for serious complications in 
jaundiced patients undergoing early surgery without PBD than in preoperatively 
stented patients(1).  The complication rate related to the stenting procedure in 
that study was, however, high (46%), whereas the rates for actual postoperative 
complications showed no significant difference. In our study, the ERCP-related 
complication rate was 4.7%, with no severe complications. The low complication rate 
is probably explained by the high volum of ERCP procedures at our hospital, with 
highly specialized endoscopists. It should be noted, however, that the population for 
our study was gathered from surgical databases, and thus, there is a possibility of 
severe ERCP-related complications preventing an originally assigned surgery. The 
quantity of such patients logically cannot be very high, as such a scenario would 
have resulted in actions against PBD. 
The issue of the choice between NEPS and SEMS has been investigated to a 
lesser extent. The substantially higher cost for SEMS speaks against its brief and 
temporary use during the preoperative course. The rationale against preoperative 
stenting is that it probably increases the risk for bacterial growth in the bile juice 
and some studies have shown this increases postoperative infection complications 
(127, 129) . It has been assumed that bacterial growth could be diminshed if large-
bore SEMS are used as they provide better biliary flow than NEPS. In this study 
there was no significant difference between the bacterial scores or the postoperative 
infection rates between the two stent types. The rate of infection complications in 
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stented patients versus UBO patients also did not differ. According to Kajiwara et 
al., a correlation exists between postoperative bacteria in the bile juice and Grade 
B and C postoperative fistulas (126) . Neither the bacterial scores in our study nor 
the use of different stent types differed across the different fistula grades. However, 
all UBO patients had sterile bile, but as the number of UBO patients in this study 
was very small relative to stented patients, a significant difference in postoperative 
(infection) complications could not be established.
Interestingly, the Dutch group, which in 2010 published the RCT favoring early 
surgery over PBD, recently published a prospective cohort study comparing PBD 
with NEPS or fcSEMS and early surgery (124) . It turns out the fcSEMS cohort 
was added to the earlier RCT, with the PBD-using-plastic stents cohort and the 
early surgery cohort as historical controls. The authors concluded the outcome for 
fcSEMS was better than that for NEPS in preoperative biliary drainage. However, 
as the PBD-related complication rate is very high in the historical PBD group, such 
a conclusion seems somewhat hasty. Furthermore, as the PBD was performed in 
different time periods, the superior results for fcSEMS may be the result of access 
to more evolved technical ERCP equipment and the endoscopists becoming more 
experienced and skilled over the years.
Even though cost-effectiveness for SEMS has been assessed in malignant 
palliative stenting, recently also for short-term stenting, no cost analyses have been 
conducted of plastic versus metallic stenting in preoperative drainage (6, 105) . 
Currently, there are a few ongoing randomized trials comparing NEPS and SEMS 
in PBD; these probably are also assessing the costs (124) .
Regarding bilirubin levels, more patients with NEPS than with SEMS reached 
levels below 20 and 50 μmol/l. The differences were insignificant, although a trend 
towards superiority of NEPS was seen when the level was set to 50 μmol/l. For 
both groups, the longer the time between stent placement and operation, the lower 
the preoperative bilirubin level. It is, on the other hand, possible that the SEMS 
affects the bile duct inducing ischemia or ductal hyperplasia impairing the bile flow.
6.4 ENDOSCOPIC COVERED SELF-EXPANDABLE METALLIC 
STENT THERAPY IN BENIGN BILIARY STRICTURES IN 
PATIENTS WITH ALTERED ANATOMY (IV)
The short length of the duodenoscope prevents its use in altered anatomy. Even 
if longer duodenoscopes were manufactured, it is unlikely they could be used, as 
advancement in the bowel would be difficult due to looping of the scope and its 
side-viewing quality. In recent years, device-assisted enteroscopes, such as DBE, 
have been used to perform ERCP in altered anatomy (137, 138) . As standard ERCP 
devices are too short for DBE, short enteroscopes have been developed. The 2.8-mm 
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narrow working channel, however, limits the use of some appliances, e.g. SEMS 
(138-141) . The narrow channel also causes stress for the endoscopist; the pushing 
in and pulling out actions of the devices are very tight. Kawashima et al. compared 
instrument insertion time using a standard 2.8-mm working channel enteroscope 
with a prototype scope of the same length but a 3.2-mm-wide channel, showing 
faster insertion with the wider channel (148) . Thus, channel width obviously affects 
procedure time.
The long afferent limb in RYGB patients diminishes the success of reaching the 
papilla with short enteroscopes. Interestingly, several modifications of surgically 
or endoscopically assisted techniques entering the gastrointestinal (GI) tract 
through the remnant stomach have been developed (4, 146, 147) . These different 
approaches reflect the complexity and difficulty of performing ERCP in altered 
anatomy, especially in cases with a long Roux-en-Y limb.
Until now, through-the-scope placement of cSEMS using a long enteroscope 
has not been feasible due to the limited diameter of the working channel and the 
inappropriate length of the stent deployment catheter. Here we report the first 
case of fcSEMS deployment through the working channel of a long DBE. The stent 
was custom-made with a delivery device longer than those for standard fcSEMS. 
The DBE used has a 3.2-mm working channel, which is wider than that of other 
commercially available balloon enteroscopes. The properties of both endoscopes 
and accessories are evolving, improving the possibilities for endoscopic treatment 
of the pancreaticobiliary tract in patients with altered anatomy. There are also 
reports of a prototype short SBE with a 3.2-mm working channel (148, 149) . This 
endoscope enables the use of standard ERCP equipment including standard SEMS. 
Still, gaining access to the blind end may be challenging using a short scope.
In our two other cases, the patients had transcutaneous routes when admitted 
for DBE. Naturally, when this route exists, this advantage should be used to perform 
a rendezvous procedure. In fact, the HJ site would not have been reached in Case 
2 without the existing PTC-route. A standard fcSEMS and delivery device can be 
inserted with the use of the transhepatic wire running along the endoscope. The 
advantage of using the rendezvous technique instead of a pure PTC technique is 
having the endoscopic view in addition to the fluoroscopic view.
Approximately one year after stent removal, the Case 2 patient suffered from 
cholangitis episodes due to hilar strictures. There was no sign of stricture on the 
stented HJ site, and the stent did not reach the hilum, and thus, it is not a case of stent-
induced de novo stricture. A recently published German study on liver-transplanted 
PSC patients showed that 28% of the patients developed nonanastomotic biliary 
strictures, with or without concomitant anastomotic stricture, in their transplant 
(155) . Recurrent PSC was seen in 20% of the patients. Benign strictures, irrespective 
of the indication for LT, have previously been found in 5–15% of patients after 
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deceased donor LT (76) . Hence, the strictures and cholangthis episodes of this 
patient may be associated with PSC and/or LT.
6.5  STENT-RELATED DRAWBACKS (I, II, III, IV)
The main downside for NEPS is their clogging in approximately 3-4 months. As 
strictures usually need a longer stent duration than this, stent exchange is necessary.
Covered SEMS, again, are prone to migrate in up to 40% of cases(14).  When the 
fcSEMS in our post-LT AS study were placed intraductally above the papilla, only one 
stent (4%; 1/24) migrated in 6% (1/18) of these patients. The cSEMS in the CP study 
also had a fairly low migration rate, (7%), although placed across the papilla. Upon 
retrieval, one Allium™ stent unravelled and one CP cSEMS broke. Furthermore, 
one CP cSEMS needed insertion of a cSEMS inside to enable removal and two 
were surprisingly broken prior to removal, a circumstance we could not explain. 
In patients with altered anatomy, stent migration could be desirable, provided it 
does not occur too soon after deployment. In Case 3 the patient had a plain X-ray 
to assess whether or not the stent was in place. This way, if migration occurs, one 
laborious and time-consuming DBE ERC could be avoided.
When cSEMS were first brought into use, there were concerns that the coverage 
would impair or occlude drainage of the cystic duct and the main pancreatic duct 
causing cholecystitis and pancreatitis, respectively. In LT patients, the gallbladder is 
removed, allowing the cystic duct to be traversed without concern. In the CP study, 
there was one acute cholecystitis in both stent groups. Both studies had only one 
case of mild PEP, and thus, neither cholecystitis nor pancreatitis appears to be an 
impending risk linked to the use of cSEMS.
Development of de novo strictures following stent therapy with cSEMS has been 
discovered(15, 21). It is likely that cSEMS, especially with high radial force, damage 
the bile duct epithelium to some extent. The clinical impact of this remains unclear. 
In our study, de novo strictures were not seen; however, neither were they sought. 
If there is a need for verifying or ruling out this entity, future ERCP reports should 
include exact measurements of the stricture length and its relative to the papilla, and 
in cases of recurrent or new strictures, the site of the previous stent must be known.
6.6  ASPECTS TO CONSIDER FOR CHOICE OF STENT (I, II, III, IV)
When choosing between stents, SEMS should clearly be preferred in malignant 
cases with a life expectancy longer than 4–6 months (6, 104) . The choice of cSEMS 
versus uSEMS in malignant strictures is, in turn, less clear. The main drawback with 
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cSEMS is migration, which diminishes both cost-effectiveness and the advantages 
of SEMS relative to NEPS.
Even more ambiguous is the choice of stents in BBS. Perhaps endoscopic 
therapy for BBS should be customized for every patient according to the stricture 
location, etiology, length, duration and special features like fibrotic firmness. Both 
multiple progressive plastic stenting and management with cSEMS appear to be 
efficacious in BBS, as shown in Study III, and patient comfort and probably also 
cost-effectiveness speak in favor of cSEMS. When choosing the cSEMS, endoscopists 
need to know and understand the features of the stent regarding radial and axial 
forces, possible antimigratory attributes and whether to place the stent across or 
above the papilla. Thus, it is probably best to know well a few carefully selected 
cSEMS with different features, acquiring experience with them in clinical use, rather 
than having numerous different types of stents available.
6.7 LIMITATIONS AND STRENGTHS OF THE STUDY
Study I is limited by its retrospective nature and the small number of patients. 
The results were also not compared with historical stent therapy with NEPS, as 
this group of patients was previously managed outside our unit. The study can be 
considered as a descriptive pilot project to determine outcome using this type of 
stent in post-LT AS. Indeed, our unit is currently participating in a multicenter study 
comparing multiple NEPS therapy with cSEMS therapy in this patient group. The 
multicenter setting is crucial, as the number of LT patients with AS in individual 
ERCP units is fairly small.
The great discrepancy in the number of patients between groups in study II 
biases the results, and affects the possibility of detecting statistically significant 
differences between the groups. Moreover, the study is of retrospective character 
and covers a long time period, and thus, other changes in the treatment protocol of 
operated patients can also have an impact on the results. Because the patients were 
gathered from a database of PD- or TP-operated patients, the possibility exists, that 
stented patients with severe PBD-complications preventing surgery were missed. 
However, the great number of NEPS patients together with their results gives some 
confidence that NEPS is a good alternative for PBD.
A bacterial score was invented in order to assign a numerical value for the 
bacterial strains and the amount of bacteria cultured from the bile juice. This score 
is not validated in any way. Moreover, it does not consider the virulence of the 
strains cultured.
The prospective RCT design of Study III is a definite advantage, especially 
considering the fact that no previous studies comparing multiple NEPS and SEMS 
in this setting have been published. However, when conceiving the study, the power 
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6. DISCUSSION
calculations were based on the contemporary belief that cSEMS would be superior 
to NEPS. Surprisingly, the different managements did not differ in outcome; a larger 
population might have revealed significant differences. The recruitment of patients 
took five years, and an increase in patients would probably require an international, 
multicenter study. As the centers taking part in the study were of different sizes, 
the distribution of the recruited patients was skewed. This study was also limited 
by the lack of cost analysis.
Limitations of Study IV include its case report nature and the low number of 
cases. A strength, again, is the endoscopic placement of fcSEMS, which has not 
previously been described using a long DBE in this patient group. Additionally, the 
detailed description of the procedures and the equipment used facilitates adaptation 
of the technique by interventional endoscopists worldwide.
Three or four interventional endoscopists performed the procedures in Studies 
I and IV, and the majority of the procedures in Studies II and III. Thus, the results 
can be biased by personal preferences. On the other hand, the limited number of 
endoscopists diminishes the diversity of the differences in experience and skills 
that a large pool of endoscopists would entail. Furthermore, the outcome of the 
procedures was mainly evaluated by the endoscopists themselves, possibly affecting 
the interpretation of the procedures.
6.8  FUTURE PERSPECTIVES
The field of stent therapy is continuously evolving, not only regarding the stents but 
also other equipment needed. Improvement of the stents with respect to patency, 
functionality, and removability along with advancement in stent therapy methods, 
are current hot topics.
Magnetic tipped plastic stents, providing for removal without repeat ERCP have 
been tested in animal models(8). The stents were removed under fluoroscopic 
control using an external magnet. The authors expressed concern regarding proximal 
migration of the stent inside the duct with improper handling of magnets. Another 
consideration is what would happen if the patient for some reason needs an MRI. 
Hence, further studies are needed for this technique.
Compared with the above, biodegradable stents form a more feasible alternative 
to avoid ERCP for retrieval of the stent, not least as there has already been 
experimental, successful human use(34). A future topic of study is whether debris 
following degradation forms a problem. Biodegradable stents appears to be an 
especially useful alternative in patients with altered anatomy. An intriguing future 
option is combining biodegradable stents with drug-eluting qualities. Shi et al. 
conducted an in vivo study on dogs using paclitaxel-coated supporting PLA stents 
when performing a cholangiojejunostomy to prevent BBS (156) . They showed that 
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paclitaxel significantly inhibited myofibroblast activation and proliferation and 
also excessive collagen deposition in the bilioenteric anastomosis. Moreover, the 
biodegradable polymer material seemed applicable in the controlled release of the 
drug. Finally, because paclitaxel has been used in coronary stents for decades, its 
use has gained trust (157) .
Despite similar surgical trauma, some patients will sustain abundant adhesions, 
while others will not. This is probably linked to the patient´s tissue type. In the future, 
maybe, susceptible tissue types can be identified, allowing the use of stents coated 
with drugs (such as paclitaxel) to reduce scar formation at surgical anastomoses or 
to prevent restricture after stent therapy in patients more prone to form scar tissue.
Other drug-eluting and radioactive properties appear to offer stent therapy 
endless possibilities, especially in the treatment of malignant strictures (36, 37).
Furthermore, ERCP equipment and supplementary devices needed in DAE 
ERCP will likely improve and evolve as their demand increases.
6.9  GENERAL ASPECTS
The subject of this thesis, although versatile, forms only a limited part of endoscopic 
management of the pancreaticobiliary tree. Interventional endoscopists must 
not only acquire skills to perform the complex procedures, knowledge about the 
techniques, equipment and devices, but also deep insight into numerous diseases, 
postoperative states and their etiologies and pathophysiologies. Hence, it is clearly 
advantageous to centralize this kind of management. The research in this field is 
active, resulting in rapid evolution of equipment, devices and techniques. However, 
managing all technically possible biliary states using ERCP is not always gaining 
the patient.
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7. SUMMARY AND CONCLUSIONS
The use of SEMS in extrahepatic biliary strictures is experimental and unclear. The 
following conclusions can be drawn from this study:
1)  Anastomotic complications after LT can be efficaciously and safely managed 
using cSEMS, especially if placed intracholedochally. The duration of stent 
therapy and the stent types need further assessment.
2)  Compared with SEMS, preoperative stenting with NEPS appears to produce 
sufficient biliary drainage.
3)  Six months of stent therapy, either with cSEMS or progressive multiple stenting 
with NEPS, is safe and efficacious in bile strictures caused by CP. Treatment 
with cSEMS adds to patient comfort and is probably cost-effective as well.
4)  Evolution of double-balloon enteroscope properties and delivery devices enables 
endoscopic deployment of cSEMS in BBS in patients with altered anatomy. If the 
patient has preceding PTC, this route can be used for rendezvous procedures.
5)  The ERCP-related complication rates are low in a high volume ERCP center.
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